1. Introduction {#sec1-marinedrugs-16-00038}
===============

Limonoids are highly oxidized tetranortriterpenoids from a biosynthetic precursor with a 4,4,8-trimethyl-17-furanylsteroid skeleton. This group of natural products has attracted considerable attention because of its abundance, fascinating structural diversity, and various biological activities \[[@B1-marinedrugs-16-00038],[@B2-marinedrugs-16-00038],[@B3-marinedrugs-16-00038],[@B4-marinedrugs-16-00038]\]. *Xylocarpus* is a well-known genus of mangrove plants which has been found to produce various types of limonoids with a broad range of bioactivities, such as insect antifeedant, antitumor, neuroprotective, gastroprotective, and antidepressant-like activities \[[@B5-marinedrugs-16-00038],[@B6-marinedrugs-16-00038],[@B7-marinedrugs-16-00038],[@B8-marinedrugs-16-00038],[@B9-marinedrugs-16-00038],[@B10-marinedrugs-16-00038],[@B11-marinedrugs-16-00038]\]. *X. moluccensis*, a true mangrove tree, is mainly distributed in Bangladesh, India, Indochina, Malesia, and tropical Australia. Previous chemical investigations of *X. moluccensis* resulted in the isolation of more than 100 limonoids with diverse carbon skeletons, such as mexicanolide, phragmalin, gedunin, andirobin, and khayanolide compounds \[[@B12-marinedrugs-16-00038],[@B13-marinedrugs-16-00038],[@B14-marinedrugs-16-00038],[@B15-marinedrugs-16-00038],[@B16-marinedrugs-16-00038],[@B17-marinedrugs-16-00038],[@B18-marinedrugs-16-00038]\]. Limonoids with diverse skeletons from *X. moluccensis* revealed structural plasticity in the limonoid biosynthesis of this mangrove species. This inference drove us to obtain and identify more novel and bioactive limonoids from this mangrove plant.

Further investigation of the seeds of *X. moluccensis* afforded fourteen mexicanolides (**1**--**14**), seven khayanolides (**15**--**21**), two unusual limonoids with a (*Z*)-bicyclo\[5.2.1\]dec-3-en-8-one substructure (**22**, **23**), two 30-ketophragmalins (**24**, **25**), two phragmalin 8,9,30-*ortho* esters (**26**, **27**), an azadirone derivative (**28**), and an andirobin derivative (**29**) ([Figure 1](#marinedrugs-16-00038-f001){ref-type="fig"}). Herein, we report the isolation, structural identification, antitumor, and anti-HIV activities of these new limonoids.

2. Results and Discussion {#sec2-marinedrugs-16-00038}
=========================

In this paper, 16 compounds (*viz*. **1**, **3**--**6**, **8**, **9**, **12**--**14**, **20**, **21**, **24**, **26**, **27**, and **29**) were obtained from seeds of the Thai *X. moluccensis*, whereas 13 compounds (*viz*. **2**, **7**, **10**, **11**, **15**--**19**, **22**, **23**, **25**, and **28**) were isolated from those of the Indian *X. moluccensis*.

Compound **1** was obtained as a colorless crystal. The molecular formula of **1** was established from the positive HRESIMS ion peak at *m*/*z* 615.2785 (calcd. for \[M + H\]^+^, 615.2800) to be C~33~H~42~O~11~, implying thirteen degrees of unsaturation. According to the ^1^H and ^13^C NMR spectroscopic data ([Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}), five elements of unsaturation were due to four ester groups, a keto carbonyl function, and three carbon-carbon double bonds; thus, the molecule was pentacyclic. The ^1^H and ^13^C NMR spectroscopic data ([Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}) showed the presence of a β-substituted furan ring \[δ~H~ 7.52 br d (*J* = 0.8 Hz H-21), 6.45 br d (*J* = 1.2 Hz H-22), 7.44 t (*J* = 1.6 Hz H-23)\], four tertiary methyl groups (δ~H~ 1.27 s H~3~-19, 1.04 s H~3~-29, 1.05 s H~3~-18, 0.84 s H~3~-28), a methoxy (δ~H~ 3.73 s H~3~-31), and a keto function (δ~C~ 216.7 qC), indicating a mexicanolide-type limonoid for **1**.

The NMR spectroscopic data of **1** ([Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}) were similar to those of khayalenoid H \[[@B19-marinedrugs-16-00038]\], except for the replacement of the 3-*O*-acetyl group in khayalenoid H by an isobutyryloxy group \[δ~H~ 2.64 m 1H, 1.22 d (*J* = 7.2 Hz 3H), 1.24 d (*J* = 7.2 Hz 3H); δ~C~ 175.9 qC, 34.5 CH, 19.9 CH~3~, 18.4 CH~3~\] in **1**. The presence of the isobutyryloxy group was corroborated by ^1^H-^1^H COSY correlations between H~3~-34/H-33 and H~3~-35/H-33. The significant HMBC correlation from H-3 (δ~H~ 4.97 s) to the carbonyl carbon (δ~C~ 175.9 qC) of the isobutyryloxy group placed it at C-3 ([Figure 2](#marinedrugs-16-00038-f002){ref-type="fig"}a).

The relative configuration of **1** was established by diagnostic NOE interactions ([Figure 2](#marinedrugs-16-00038-f002){ref-type="fig"}b). Those between H-17/H-11β, H-17/H-12β, H-17/H-5, and H-5/H~3~-28 revealed their cofacial relationship, and were arbitrarily assigned as the β-oriented H-17 and H-5. NOE interactions between H-9/H-12α, H-9/H~3~-19, H~3~-18/H-12α, H-3/H~3~-29, and 2-OH/H~3~-29 assigned the α-orientation for H-9, H~3~-18, H~3~-19, H-3, and 2-OH.

In order to establish the absolute configuration of **1**, single-crystal X-ray diffraction analysis with Cu Kα radiation (Flack parameter of −0.06 (10), Flack x of −0.14 (11), and Hooft y of −0.04 (3); suitable crystals of **1** were obtained from acetone/methanol (1:2) at room temperature) was employed, which unequivocally assigned the absolute configuration of **1** as 2*R*,3*S*,5*S*,6*R*,9*S*,10*R*,13*R*,17*R*. The computer-generated perspective drawing of the X-ray structure of **1** is shown in [Figure 3](#marinedrugs-16-00038-f003){ref-type="fig"}. Therefore, the absolute configuration of **1** named xylomolin A~1~ was assigned as shown ([Figure 2](#marinedrugs-16-00038-f002){ref-type="fig"}a).

Compound **2** was obtained as an amorphous white powder. The molecular formula was determined to be C~30~H~38~O~10~ by the negative HRESIMS ion peak at *m*/*z* 593.2143 (calcd. for \[M + Cl\]^−^, 593.2159). The NMR spectroscopic data of **2** resembled those of **1** ([Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}), except for the replacement of the 3-*O*-isobutyryl moiety and the 6-*O*-acetyl group in **1** by a 3-*O*-propionyl moiety (δ~H~ 2.45 m 1H, 2.43 m 1H, 1.20 t (*J* = 7.6 Hz 3H); δ~C~ 173.3 qC, 28.0 CH~2~, 9.4 CH~3~) and a 6-OH group in **2**, respectively. The presence of a 3-*O*-propionyl moiety was confirmed by ^1^H-^1^H COSY correlations between H~3~-34/H~2~-33 and HMBC cross-peaks between H~3~-34/C-33, H~3~-34/C-32, H~2~-33/C-32, and H-3/C-32. The relative configuration of **2** (except for that of C-6) was determined to be the same as that of **1** by NOE interactions between H-17/H-15β, H-15β/H-30β, H-17/H-12β, H-17/H-11β, H-11β/H-5, H-17/H-5, and H-5/H~3~-28, and those between H-9/H~3~-19, H~3~-19/H~3~-29, H~3~-29/H-3, and H~3~-18/H-15α. Thus, the structure of **2**---named xylomolin A~2~---was assigned as shown in [Figure 1](#marinedrugs-16-00038-f001){ref-type="fig"}.

Compound **3** gave the molecular formula C~32~H~42~O~11~ as established by the HRESIMS ion peak at *m*/*z* 625.2620 (calcd. for \[M + Na\]^+^, 625.2619). The NMR spectroscopic data of **3** ([Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}) were similar to those of moluccensin S \[[@B20-marinedrugs-16-00038]\], except for the presence of an additional 30-OH group, which was supported by the downshifted C-30 signal (δ~C~ 73.0 CH in **3**, whereas δ~C~ 44.6 CH~2~ in moluccensin S) and HMBC correlations from the proton of 30-OH to C-30, C-2, and C-8. NOE interactions between H-17/H-12β, H-17/H-11β, H-5/H-12β, H-5/H-17, H-5/H~3~-28, and H-5/H-30 revealed the β-orientation for H-5, H-17, H-30, and H~3~-28, and the corresponding 30α-OH. Similarly, those between H-3/2-OH, H~3~-29/2-OH, H-9/H~3~-19, H~3~-29/H~3~-19, and H~3~-18/H-11α assigned the α-orientation for H-3, H-9, H~3~-18, H~3~-19, H~3~-29, and 2-OH. Thus, the structure of **3**---named xylomolin A~3~---was determined to be 30α-hydroxy-moluccensin S.

Compound **4** provided the molecular formula of C~34~H~44~O~13~ as determined from the positive HRESIMS ion peak at *m*/*z* 683.2675 (calcd. for \[M + Na\]^+^, 683.2674). The ^1^H and ^13^C NMR spectroscopic data of **4** resembled those of **3** ([Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}), the difference being the presence of a 15-OH function (δ~H~ 3.66 br s) and a 6-acetoxy group (δ~H~ 2.18 s 3H; δ~C~ 169.8 qC, 21.0 CH~3~) in **4**. The existence of a 15-OH function was corroborated by the downshifted C-15 signal (δ~C~ 65.4 CH in **4**, whereas δ~C~ 32.8 CH~2~ in **3**) and HMBC correlations from the proton of 15-OH to C-14, C-15, and C-16. The HMBC correlation from H-6 to the carbonyl carbon (C-37) of the acetoxy group placed it at C-6. The relative configuration of **4** (except that of C-15) was assigned as the same as that of **3** on the basis of NOE interactions. Those between H-17/H-15 and H-5/H-30 assigned the β-oriented H-15 and H-30, and the corresponding 15α-OH group. Consequently, the structure of **4**---named xylomolin A~4~---was identified as 15α-hydroxy-6-acetoxy-xylomolin A~3~.

The molecular formula of **5** was determined to be C~31~H~38~O~12~ by the positive HRESIMS ion peak at *m*/*z* 625.2252 (calcd. for \[M + Na\]^+^, 625.2255). The ^1^H and ^13^C NMR spectroscopic data of **5** ([Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}) were closely related to those of khayalenoid H, the difference being the existence of a 30-OH function, which was supported by the downshifted C-30 signal (δ~C~ 72.9 CH in **5**, whereas δ~C~ 44.4 CH~2~ in khayalenoid H). HMBC correlations from the proton of 30-OH (δ~H~ 2.67 br s) to C-30 and C-8 demonstrated the above deduction. The NOE interaction between H-5/H-30 assigned the β-oriented H-30 and the corresponding 30α-OH. Thus, the structure of **5**---named xylomolin A~5~---was assigned as 30α-hydroxy-khayalenoid H.

Compound **6** was isolated as a white and amorphous powder. Its molecular formula was determined to be C~31~H~38~O~11~ from the positive HRESIMS ion peak at *m*/*z* 609.2311 (calcd. for \[M + Na\]^+^, 609.2306). The ^1^H and ^13^C NMR spectroscopic data of **6** ([Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}) closely resembled those of khayalenoid H \[[@B19-marinedrugs-16-00038]\], except for the replacement of the 2-OH function and the 6-*O*-acetyl group in khayalenoid H by a 2-*O*-acetyl (δ~H~ 2.13 s 3H; δ~C~ 169.1 qC, 21.8 CH~3~) and a 6-OH group (δ~H~ 2.80 br s) in **6**, respectively. HMBC correlations from the proton of the 6-OH group to C-5, C-6,and C-7 placed it at C-6. The presence of the 2-*O*-acetyl group in **6** was corroborated by the downshifted C-2 in **6** (δ~C~ 86.5 qC in **6**, whereas δ~C~ 77.9 qC in khayalenoid H). HMBC correlations from H~2~-30 and H-3 to C-2 confirmed the above deduction. The relative configuration of **6** was determined to be the same as that of khayalenoid H based on diagnostic NOE interactions between H-17/H-15β, H-17/H-12β, H-17/H-5, and H-5/H~3~-28 and those between H-9/H~3~-19, H~3~-19/H~3~-29, and H~3~-18/H-15α. Therefore, the structure of **6**---named xylomolin A~6~---was determined to be 2-*O*-acetyl-6-*O*-deacetyl-khayalenoid H.

The molecular formula of **7** was determined to be C~31~H~38~O~10~ by the positive HRESIMS ion peak at *m*/*z* 593.2358 (calcd. for \[M + Na\]^+^, 593.2357). The ^1^H and ^13^C NMR spectroscopic data of **7** ([Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}) were closely related to those of **6**, except for the absence of the 6-OH group, which was corroborated by the upshifted CH~2~-6 signal (δ~H~ 2.32 dd (*J* = 16.5, 1.6 Hz), 2.42 dd (*J* = 16.5, 10.7 Hz), δ~C~ 33.3) in **7**. ^1^H-^1^H COSY correlations between H~2~-6/H-5 and HMBC cross-peaks from H~2~-6 and C-5 and C-7 confirmed the above result. The analysis of diagnostic NOE interactions revealed that **7** possessed the same relative configuration as that of **6**. Therefore, the structure of **7**---named xylomolin A~7~---was assigned as 6-dehydroxy-xylomolin A~6~.

Compound **8** was isolated as a white and amorphous powder. It had a molecular formula of C~31~H~36~O~11~ as deduced from the positive HRESIMS ion peak at *m*/*z* 607.2151 (calcd. for \[M + Na\]^+^, 607.2150). The ^1^H and ^13^C NMR spectroscopic data of **8** ([Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}) were similar to those of heytrijunolide E \[[@B21-marinedrugs-16-00038]\] with Δ^8,9^ and Δ^14,15^ conjugated double bonds, except for the absence of the 15-OH group and the presence of an acetoxy group at C-3 in **8**. The absence of the 15-OH group was confirmed by the upshifted C-15 signal (δ~C~ 111.6 qC in **8**, whereas δ~C~ 134.7 qC in heytrijunolide E) and HMBC correlations between H-15/C-14, H-15/C-16, H-15/C-8, and H-15/C-13. The HMBC correlation from H-3 (δ~H~ 5.51 s) to the carbonyl carbon (δ~C~ 170.2 qC) of the acetoxy group placed it at C-3. The relative configuration of **8** was established to be the same as that of heytrijunolide E based on diagnostic NOE interactions between H~3~-28/H-5, H-5/H-11β, H-12β/H-17, H~3~-29/H-3, H-12α/H~3~-18, and H-11α/H~3~-19. Therefore, the structure of **8**---named xylomolin B~1~---was assigned as 15-dehydroxy-3β-acetoxy-heytrijunolide E.

Compound **9** provided the molecular formula C~29~H~34~O~9~ as established by the positive HRESIMS ion peak at *m*/*z* 527.2273 (calcd. for \[M + H\]^+^, 527.2276). The ^1^H and ^13^C NMR spectroscopic data of **9** ([Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}) were similar to those of heytrijunolide E \[[@B21-marinedrugs-16-00038]\], the difference being the absence of the 2-OH and 15-OH groups in **9**, which was corroborated by the upshifted C-15 (δ~C~ 110.6 CH in **9**, whereas δ~C~ 134.7 qC in heytrijunolide E) and C-2 (δ~C~ 50.5 CH in **9**, whereas δ~C~ 78.2 qC in heytrijunolide E) signals. A proton (δ~H~ 3.02 t (*J* = 6.0 Hz)) exhibiting ^1^H-^1^H COSY correlations to H-3 and H-30 and HMBC cross-peaks to C-1, C-3, C-4, and C-30 was assigned as H-2. The existence of H-15 (δ~H~ 5.89 s) was further confirmed by its HMBC correlations to C-8, C-13, C-14, and C-16. The relative configuration of **9** was determined to be the same as that of heytrijunolide E based on diagnostic NOE interactions between H~3~-28/H-5, H-5/H-11β, H-12β/H-17, H~3~-29/H-3, H-12α/H~3~-18, and H-11α/H~3~-19. Thus, the structure of **9**---named xylomolin B~2~---was assigned as 2,15-dedihydroxy-heytrijunolide E.

Compound **10** had a molecular formula of C~29~H~34~O~10~ as determined from the positive HRESIMS ion peak at *m*/*z* 543.2238 (calcd. for \[M + H\]^+^, 543.2230). The NMR data of **10** ([Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}) closely resembled those of moluccensin U \[[@B20-marinedrugs-16-00038]\], except for the replacement of the 3-*O*-(2-methyl)butyryl group in moluccensin U by an acetoxy group (δ~H~ 2.22 s 3H; δ~C~ 169.9 qC, 20.7 CH~3~) in **10**. The significant HMBC cross-peak from H-3 (δ~H~ 4.83 s) to the carbonyl carbon of the above acetoxy group placed it at C-3. NOE interactions between H-11β/H-17, H-12β/H-17, H-11β/H-5, H-5/H~3~-28, H-9/H~3~-18, H-9/H~3~-19, and H~3~-29/H-3 revealed the same relative configuration of **10** as that of moluccensin U. Therefore, the structure of **10**---named xylomolin C~1~---was assigned as 3-*O*-acetyl-3-de(2-methyl) butyryloxy-moluccensin U.

Compound **11** afforded the molecular formula C~32~H~40~O~9~ as established by the positive HRESIMS ion peak at *m*/*z* 591.2570 (calcd. for \[M + Na\]^+^, 591.2565). The ^1^H and ^13^C NMR spectroscopic data of **11** ([Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}) closely resembled those of swietmanin G \[[@B22-marinedrugs-16-00038]\], the difference being the replacement of the 3-isobutyryloxy group in swietmanin G by a 2-methylbutyryloxy group (δ~H~ 2.57 m 1H, 1.61 m 1H, 1.81 m 1H, 1.04 t (*J* = 7.2 Hz 3H), 1.25 d (*J* = 6.8 Hz 3H); δ~C~ 176.0 qC, 41.4 CH, 26.9 CH~2~, 11.9 CH~3~, 17.0 CH~3~) in **11**. The deduction was confirmed by ^1^H-^1^H COSY correlations between H~3~-36/H-33, H~3~-35/H~2~-34, and H~2~-34/H-33, and HMBC correlations between H-3/C-32, H~3~-35/C-34, H~3~-35/C-33, H~3~-36/C-33, H~3~-36/C-32, and H~3~-36/C-34. NOE interactions between H-12β/H-17, H-17/H-11β, H-5/H-11β, H-5/H~3~-28, H-9/H~3~-18, H-9/H~3~-19, and H~3~-29/H-3 assigned the α-orientation for H-9, H~3~-18, H~3~-19, and H-3. Thus, the structure of **11**---named xylomolin C~2~---was assigned as 3-*O*-(2-methyl)butyryl-3-deisobutyryloxy-swietmanin G.

Compound **12** had the molecular formula C~32~H~42~O~11~ as determined from the positive HRESIMS ion peak at *m*/*z* 625.2612 (calcd. for \[M + Na\]^+^, 625.2619). The ^1^H and ^13^C NMR spectroscopic data of **12** ([Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}) were similar to those of moluccensin U \[[@B20-marinedrugs-16-00038]\], except for the absence of the Δ^8,30^ double bond and the presence of an 8-OH group. This finding was verified by the upshifted C-8 (δ~C~ 71.3 qC) and C-30 (δ~C~ 45.9 CH~2~) signals as compared with those (δ~C~ 134.5 qC and 133.6 CH) of moluccensin U, respectively. The presence of the 8-OH group was confirmed by HMBC correlations from its proton to C-8, C-9, and C-30. NOE interactions between 8-OH/H-9 and 8-OH/H~3~-18 assigned the α-orientation for the 8-OH group. The relative configuration of **12** (except that of C-8) was established to be identical to that of moluccensin U based on diagnostic NOE interactions between H-12β/H-17, H-5/H~3~-28, H-9/H~3~-19, and H~3~-29/H-3. Thus, the structure of **12**---named xylomolin D---was assigned as 8,30-dihydrogen-8α-hydroxy-moluccensin U.

Compound **13** was obtained as an amorphous white power. The molecular formula was determined to be C~31~H~38~O~12~ by the positive HRESIMS ion peak at *m*/*z* 625.2250 (calcd. for \[M + Na\]^+^, 625.2255). The ^1^H and ^13^C NMR spectroscopic data of **13** ([Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}) were similar to those of **8**, except for the replacement of Δ^8,9^ and Δ^14,15^ conjugated double bonds in **8** by a Δ^8,30^ double bond (δ~C~ 138.8 qC C-8, 130.2 CH C-30) in **13**, and the presence of an additional 14-OH group. HMBC correlations between H~2~-15/C-14, H~2~-15/C-16, H~2~-15/C-13, H-30/C-14, H-30/C-9, and H-9/C-8 demonstrated the above deduction. In order to establish the relative configuration of the 14-OH group in **13**, two possible 3D structures with a 14α-OH and 14β-OH groups, respectively, were simulated by using the ChemBio3D software ([Figure 4](#marinedrugs-16-00038-f004){ref-type="fig"}). When the 14-OH group occupies α-orientation, the space distance between H-5/H-17 is around 2.4 Å ([Figure 4](#marinedrugs-16-00038-f004){ref-type="fig"}a), implying the presence of a strong NOE interaction between these protons. On the contrary, when the 14-OH group occupies the β-orientation, the space distance between H-5/H-17 is around 5.8 Å ([Figure 4](#marinedrugs-16-00038-f004){ref-type="fig"}b), indicating the absence of a NOE interaction between these protons. Quite evidently, the NOE interaction between H-5/H-17 could be utilized as an effective criterion to resolve the relative configuration of the 14-OH group. Thus, the orientation of the 14-OH group in **13** was assigned as α based on the strong NOE interaction between H-5/H-17. Furthermore, the relative configuration of the whole molecule of **13** (except that of C-14) was determined to be the same as that of **8** on the basis of NOE interactions between H~3~-28/H-5, H-5/H-11β, H-12β/H-17, H~3~-29/H-3, H-12α/H~3~-18, and H-11α/H~3~-19. Thus, the structure of **13**---named xylomolin E---was assigned as depicted.

Compounds **2**--**13** are analogues of **1**. From the point of view of biogenetic origins, these mexicanolides should possess the same absolute configurations of carbon skeletons as that of **1**. The absolute sterostructures of **2**--**13** are shown as in [Figure 1](#marinedrugs-16-00038-f001){ref-type="fig"}.

The molecular formula of **14** was determined to be C~33~H~42~O~13~ by the positive HRESIMS ion peak at *m*/*z* 669.2521 (calcd. for \[M + Na\]^+^, 669.2518). The NMR spectroscopic data of **14** ([Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}) were similar to those of xylorumphiin H \[[@B23-marinedrugs-16-00038]\], being a mexicanolide containing a C1-*O*-C8 bridge, except for the presence of an additional Δ^14,15^ double bond (δ~H~ 6.08 s 1H; δ~C~ 158.3 qC, 118.4 CH) and an additional 6-OH function (δ~H~ 2.93 s) in **14**. The existence of the Δ^14,15^ double bond was corroborated by HMBC correlations between H~3~-18/C-14, H-15/C-8, and H-15/C-16. The downshifted C-6 signal (δ~C~ 71.7 CH in **14**, whereas δ~C~ 32.3 CH~2~ in xylorumphiin H), along with HMBC cross-peaks from H-6 to C-5 and C-7, supported the location of a hydroxy group at C-6. Similar NOE interactions of **14** as those of xylorumphiin H suggested that both mexicanolides possessed the same relative configuration. Thus, the structure of **14**---named xylomolin F---was assigned as 6-hydroxy-14,15-dedihydrogen-xylorumphiin H.

The molecular formula of **15** was established by the positive HRESIMS ion peak at *m*/*z* 587.2494 (calcd. for \[M + H\]^+^, 587.2492) to be C~31~H~38~O~11~, implying thirteen degrees of unsaturation. According to the NMR spectroscopic data of **15** ([Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}), seven elements of unsaturation were due to three carbon-carbon double bonds, one carbonyl group, and three ester functionalities; thus, **15** should be hexacyclic. The NMR spectroscopic data of **15** resembled those of thaixylomolin L \[[@B18-marinedrugs-16-00038]\], being a khayanolide isolated from seeds of the Thai *X. moluccensis*, except for the presence of an additional 6-OH group in **15**. Strong ^3^*J* HMBC correlations from H~2~-29 to C-30 further confirmed a khayanolide for **15** instead of a phragmalin, which should exhibit weak ^4^*J* HMBC correlations between H~2~-29/C-30. HMBC cross-peaks from an active proton (δ~H~ 2.91 d (*J* = 3.4 Hz)) to C-5 (δ~C~ 45.4, CH), C-6 (δ~C~ 72.0, CH), and C-7 (δ~C~ 175.3, qC) ([Figure 5](#marinedrugs-16-00038-f005){ref-type="fig"}a) revealed the existence of a 6-OH group in **15**.

The relative configuration of **15** was assigned by analysis of NOE interactions ([Figure 5](#marinedrugs-16-00038-f005){ref-type="fig"}b). Those between H-17/H-12β, H-17/H-15β, H-17/H-11β, and H-11β/H-5 revealed their cofacial relationship and were assigned as β-oriented. In turn, NOE interactions between H~3~-18/H-15α, H-9/H~3~-19, H~3~-19/1-OH, and H-34/H~pro-*R*~-29 indicated the α-orientation for H-9, H~3~-18, H~3~-19, 1-OH, and 30-OEt. The NOE interaction between H-3/H~pro-*R*~-29 established the 3α-H and the corresponding 3β-acetoxy function. Therefore, the relative configuration of **15** was determined. Comparison of the electronic circular dichroism (ECD) spectrum of **15** with that of thaixylomolin L \[[@B18-marinedrugs-16-00038]\] showed that **15** had the same 1*R*,3*S*,4*R*,5*S*,9*R*,10*S*,13*R*,17*R*,30*S*-absolute configuration as that of thaixylomolin L ([Figure 6](#marinedrugs-16-00038-f006){ref-type="fig"}a). Thus, the structure of **15**---named xylomolin G~1~---was assigned as depicted.

Compound **16** had a molecular formula of C~33~H~42~O~11~ as determined from the positive HRESIMS ion peak at *m*/*z* 615.2809 (calcd. for \[M + H\]^+^, 615.2805). The NMR spectroscopic data of **16** ([Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}) were closely related to those of **15**, the difference being the replacement of 3-acetoxy group in **15** by an isobutyryloxy group (δ~H~ 2.57 m, 1.20 d (*J* = 7.2 Hz), 1.22 d (*J* = 7.2 Hz); δ~C~ 176.0 qC, 33.8 CH, 19.0 CH~3~, 19.1 CH~3~) in **16**. The presence of the above isobutyryloxy group was further supported by ^1^H-^1^H COSY correlations between H~3~-34/H-33 and H~3~-35/H-33, and HMBC correlations between H-33/C-32, H~3~-34/C-32, and H~3~-35/C-32. The significant HMBC cross-peak from H-3 to the carbonyl carbon (C-32) of the isobutyryloxy group confirmed its location at C-3. NOE interactions between H-17/H-12β, H-17/H-15β, H-17/H-11β, H-11β/H-5, H-17/H-5, H-5/H~3~-28, H-3/H~pro~-*~R~*-29, H-15α/H~3~-18, H~3~-18/H-9, H-9/H~3~-19, and 1-OH/H-9 indicated the same relative configuration of **16** as that of **15**. Comparison of the ECD spectrum of **16** with that of thaixylomolin L concluded that **16** had the same 1*R*,3*S*,4*R*,5*S*,9*R*,10*S*,13*R*,17*R*,30*S*-absolute configuration as that of thaixylomolin L ([Figure 6](#marinedrugs-16-00038-f006){ref-type="fig"}a). Thus, the structure of **16**---named xylomolin G~2~---was assigned as 3-*O*-isobutyryl-3-deacetoxy-xylomolin G~1~.

Compound **17** was isolated as an amorphous yellow solid. Its molecular formula was determined to be C~29~H~34~O~10~ by the positive HRESIMS ion peak at *m*/*z* 543.2246 (calcd. for \[M + H\]^+^, 543.2230). The similarities between the NMR spectroscopic data of **17** ([Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}) and **15** revealed their close structural resemblance, except for the absence of the ethoxyl group at C-30, which was confirmed by the upshifted C-30 signal (δ~C~ 63.0 CH in **17**, whereas δ~C~ 92.2 qC in **15**) and HMBC cross-peaks between H-30/C-1, H-30/C-2, H-30/C-8, and H-30/C-10. The relative configuration of **17** was determined to be identical to that of **15** by analysis of NOE interactions. Comparison of ECD spectra of **17** and **15** concluded that both compounds had the same 1*R*,3*S*,4*R*,5*S*,9*R*,10*S*,13*R*,17*R*,30*S*-absolute configuration ([Figure 6](#marinedrugs-16-00038-f006){ref-type="fig"}a). Thus, the structure of **17**---named xylomolin G~3~---was assigned as 30-deethoxyl-xylomolin G~1~.

Compound **18** provided the molecular formula C~31~H~38~O~9~ as established by the positive HRESIMS ion peak at *m*/*z* 555.2593 (calcd. for \[M + H\]^+^, 555.2594). The NMR spectroscopic data of **18** ([Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}) were similar to those of **15**, the difference being the absence of the 30-ethoxyl group and the 6-OH function in **18**. The upshifted C-30 (δ~C~ 63.4 CH in **18**, whereas δ~C~ 92.2 qC in **15**) and C-6 (δ~C~ 34.2 CH~2~ in **18**, whereas δ~C~ 72.1 CH in **15**) signals and HMBC cross-peaks between H-30/C-1, H-30/C-2, H-30/C-8, H-30/C-10, H-6/C-5, and H-6/C-7 supported the above deduction. The relative and absolute configurations of **18** were determined to be the same as that of **15** by analysis of their NOE interactions and ECD spectra ([Figure 6](#marinedrugs-16-00038-f006){ref-type="fig"}a). Thus, the structure of **18**---named xylomolin G~4~---was concluded to be 30-deethoxyl-6-dehydroxy-xylomolin G~1~.

Compound **19** gave the molecular formula C~32~H~40~O~9~ as determined from the positive HRESIMS ion peak at *m*/*z* 569.2753 (calcd. for \[M + H\]^+^, 569.2751). The NMR data of **19** ([Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}) were closely related to those of **18**, except for the replacement of the 3-isobutyryloxy group in **18** by a 2-methylbutyryloxy group (δ~H~ 2.47 m 1H, 1.73 m 1H, 1.52 m 1H, 0.94 t (*J* = 7.2 Hz 3H), 1.19 d (*J* = 7.2 Hz 3H); δ~C~ 176.0 qC, 40.8 CH, 26.7 CH~2~, 11.5 CH~3~, 16.5 CH~3~) in **19**. The presence of the 2-methylbutyryloxy group was supported by the ^1^H-^1^H COSY correlations between H-33/H-34, H-33/H~3~-36, and H-34/H~3~-35 and HMBC cross-peaks between H-33/C-32, H~2~-34/C-32, H~3~-36/C-32, H~3~-36/C-34, and H~3~-35/C-33. The significant HMBC cross-peak from H-3 to the carbonyl carbon (C-32) of the above 2-methylbutyryloxy group assigned its location at C-3. The relative and absolute configurations of **19** were determined to be the same as those of **18** by analysis of their NOE interactions and ECD spectra ([Figure 6](#marinedrugs-16-00038-f006){ref-type="fig"}a). Thus, the structure of **19**---named xylomolin G~5~---was assigned as 3-*O*-(2-methyl)butyryl-3-deisobutyryloxy-xylomolin G~4~.

Compound **20** was isolated as an amorphous white powder. Its molecular formula was determined to be C~33~H~40~O~13~ by the positive HRESIMS ion peak at *m*/*z* 667.2359 (calcd. for \[M + Na\]^+^, 667.2361). The NMR spectroscopic data of **20** ([Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}) resembled those of **15**, except for the presence of an additional 8-OH group (δ~H~ 5.00 s) and the replacement of the Δ^8,14^ double bond, 1-OH function, and 30-ethoxyl group in **15** by a Δ^14,15^ double bond (δ~H~ 5.72 br s H-15; δ~C~ 160.0 qC C-14, 120.2 CH C-15), a 1-*O*-isobutyryl moiety (δ~H~ 2.55 m H-35, 1.11 d (*J* = 7.2 Hz H~3~-36), 1.10 d (*J* = 7.2 Hz H~3~-37); δ~C~ 176.0 qC C-34, 35.1 CH C-35, 19.4 CH~3~ C-36, 19.3 CH~3~ C-37), and a 30-OH group (δ~H~ 4.87 s) in **20**, respectively ([Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}, recorded in CDCl~3~). HMBC correlations between H-15/C-14, H-15/C-16, H-15/C-13, H-15/C-8, 8-OH/C-8, and 30-OH/C-30 confirmed the presence of a Δ^14,15^ double bond and the existence of two hydroxy groups at C-8 and C-30, respectively. The presence of the isobutyryloxy group was supported by ^1^H-^1^H COSY cross-peaks between H-35/H~3~-36 and H-35/H~3~-37 and HMBC correlations between H-35/C-34, H~3~-36/C-34, and H~3~-37/C-34. Its location at C-1 was corroborated by the downshifted C-1 signal (δ~C~ 92.6 qC in **20**, whereas δ~C~ 84.5 qC in **15**). The relative configuration of **20** was established by NOE interactions, in which those between H-17/H-12β, H-12β/H-5, H-5/H~3~-28 assigned the β-orientation for H-17, H-5, H~3~-28, whereas those between H-11α/H~3~-18, H~3~-18/8-OH, 8-OH/H-9, H~pro-*R*~-29/H-3, H-9/H~3~-19, and H-3/30-OH concluded the α-orientation for H~3~-18, 8-OH, H-9, H-3, H~3~-19, and 30-OH. Thus, the structure of **20**---named xylomolin H---was assigned as depicted.

Compound **21** afforded the molecular formula C~32~H~38~O~11~ as deduced from the positive HRESIMS ion peak at *m*/*z* 621.2304 (calcd. for \[M + Na\]^+^, 621.2306). The NMR spectroscopic data of **21** ([Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}) were similar to those of thaixylomolin H \[[@B18-marinedrugs-16-00038]\], except for the presence of an additional 6-OH group (δ~H~ 3.19 s) and the replacement of the 2-acetoxy group by a 2-methylbutyryloxy moiety (δ~H~ 2.42 m 1H, 1.73 m 1H, 1.48 m 1H, 0.97 t (*J* = 7.6 Hz 3H), 1.22 d (*J* = 7.2 Hz 3H); δ~C~ 176.0 qC, 41.3 CH, 26.5 CH~2~, 11.7 CH~3~, 17.2 CH~3~) in **21**. The presence of the 6-OH group was supported by the downshifted C-6 signal (δ~C~ 71.0 CH in **21**, whereas δ~C~ 31.6 CH~2~ in thaixylomolin H), the ^1^H-^1^H COSY cross-peak between H-5/H-6, and HMBC correlations between H-6/C-5 and H-6/C-7. The existence of the 2-methylbutyryloxy group was corroborated by ^1^H-^1^H COSY cross-peaks between H-33/H~3~-36, H-33/H-34, and H~2~-34/H~3~-35 and HMBC correlations between H-33/C-32, H-34/C-32, H~3~-36/C-32, H-33/C-34, H~3~-36/C-34, H~3~-35/C-34, H-34/C-33, H~3~-35/C-33, and H~3~-36/C-33. The significant HMBC correlation from H-2 to the carbonyl carbon (C-32) of the 2-methylbutyryloxy group placed it at C-2. NOE interactions between H-17/H-12β, H-11α/H~3~-19, H-11α/H~3~-18, H-11β/H-5, H-5/H~3~-28, H~3~-19/1-OH, H~pro-*R*~-29/H-2, and H-2/30-OH assigned the β-orientation for H-17, H~3~-28, and H-5, and the α-orientation for H-2, H~3~-18, H~3~-19, 30-OH, and 1-OH. The ECD spectrum of **21** was identical to that of thaixylomolin H ([Figure 6](#marinedrugs-16-00038-f006){ref-type="fig"}b), concluding that **21** had the same 1*R*,2*R*,4*R*,5*R*,10*S*,13*R*,17*R*,30*R*-absolute configuration as that of thaixylomolin H. Thus, the structure of **21**---named xylomolin I---was identified as 6-hydroxy-2-*O*-(2-methyl)butyryl-2-deacetoxy-thaixylomolin H.

Compound **22** had the molecular formula C~29~H~32~O~10~ as determined from the positive HRESIMS ion peak at *m*/*z* 541.2077 (calcd. for \[M + H\]^+^, 541.2074). The similarities between the NMR spectroscopic data of **22** ([Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}) and those of trangmolin F \[[@B16-marinedrugs-16-00038]\], containing a (*Z*)-bicyclo\[5.2.1\]dec-3-en-8-one substructure, revealed their close structural resemblance. However, the 3-*O*-isobutyryl function in trangmolin F was replaced by an acetoxy group (δ~H~ 2.17 s 3H; δ~C~ 170.4 qC, 20.6 CH~3~) in **22**, being unambiguously confirmed by HMBC cross-peaks between H-3/C-32 and H~3~-33/C-32 ([Figure 7](#marinedrugs-16-00038-f007){ref-type="fig"}a). The relative configuration of **22** was assigned by NOE interactions ([Figure 7](#marinedrugs-16-00038-f007){ref-type="fig"}b). Those between H-17/H-12β, H-12β/H~3~-19, and H~3~-19/H-5 revealed their cofacial relationship and were determined as β-oriented, whereas those between H-3/H-9, H~pro-*R*~-29/H-3, and H-12α/H~3~-18 indicated the α-orientation for H-3, H-9, and H~3~-18, and the corresponding 3β-acetoxy function. The ECD spectrum of **22** was nicely matched with that of trangmolin F ([Figure 8](#marinedrugs-16-00038-f008){ref-type="fig"}a), concluding that the absolute configuration of **22** was the same as that of trangmolin F. Thus, the structure of **22**---named xylomolin J~1~---was assigned as 3-*O*-acetyl-3-deisobutyryloxy-trangmolin F.

Compound **23** provided the molecular formula of C~32~H~38~O~10~ as established by the positive HRESIMS ion peak at *m*/*z* 583.2548 (calcd. for \[M + H\]^+^, 583.2543). The NMR spectroscopic data of **23** ([Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}) resembled those of **22**, except for the replacement of the 3-acetoxy group in **22** by a 2-methylbutyryloxy moiety (δ~H~ 2.51 m 1H, 1.53 m 1H, 1.74 m 1H, 0.96 t (*J* = 7.2 Hz, 3H), 1.18 d (*J* = 7.2 Hz, 3H); δ~C~ 176.2 qC, 40.7 CH, 26.6 CH~2~, 11.5 CH~3~, 16.4 CH~3~) in **23**. The presence of the 2-methylbutyryloxy group was further evidenced by ^1^H-^1^H COSY cross-peaks between H-33/H~3~-36, H-33/H~2~-34, and H~2~-34/H~3~-35 and HMBC correlations between H-33/C-32, H-34/C-32, and H~3~-36/C-32. The HMBC correlation from H-3 to the carbonyl carbon (C-32) of the above 2-methylbutyryloxy group placed it at C-3. The relative configuration of **23** was confirmed to be the same as that of **22** by analysis of NOE interactions. Comparison of ECD spectra of compounds **23**, **22**, and trangmolin F ([Figure 8](#marinedrugs-16-00038-f008){ref-type="fig"}a) revealed that these compounds had the same absolute configuration. The absolute configuration of C-6 was further determined by the modified Mosher α-methoxy-α-(trifluoromethyl)phenylacetyl (MTPA) ester method \[[@B24-marinedrugs-16-00038]\]. The ∆δ values of H-5, H~3~-19, and H~3~-29 were positive, while that of H~3~-31 was negative ([Figure 8](#marinedrugs-16-00038-f008){ref-type="fig"}b). This regular arrangement concluded the *R-*absolute configuration for C-6. Finally, the absolute configuration of **23**---named xylomolin J~2~---was unequivocally established as 3*S*,4*R*,5*S*,6*R*,9*S*,10*R*,13*R*,17*R.*

Compound **24** had the molecular formula C~32~H~38~O~11~ as determined from the positive HRESIMS ion peak at *m*/*z* 621.2306 (calcd. for \[M + Na\]^+^, 621.2306). The NMR spectroscopic data of **24** ([Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}) were similar to those of moluccensin I \[[@B25-marinedrugs-16-00038]\], except for the presence of an additional 6-OH group (δ~H~ 3.12 br s) and the replacement of the 1-*O*-isobutyryl group in moluccensin I by a 1-OH function (δ~H~ 2.81 s) in **24**. The downshifted C-6 signal (δ~C~ 71.5 CH in **24**, whereas δ~C~ 33.2 CH~2~ in moluccensin I) and HMBC correlations from the active proton (δ~H~ 3.12 br s) to C-5, C-6, and C-7 revealed the presence of the 6-OH group ([Figure 9](#marinedrugs-16-00038-f009){ref-type="fig"}a). The existence of the 1-OH function was confirmed by the upshifted C-1 signal (δ~C~ 85.8 qC in **24**, whereas δ~C~ 90.8 qC in moluccensin I) and strong HMBC cross-peaks from the active proton (δ~H~ 2.81 s) to C-1, C-2, and C-10 ([Figure 9](#marinedrugs-16-00038-f009){ref-type="fig"}a). The relative configuration of **24** was identified as the same as that of moluccensin I based on NOE interactions between H-17/H-12β, H-5/H-11β, H-5/H-28, H~3~-18/H-11α, H~3~-19/H*~pro-S~*-29, H-3/H*~pro-R~*-29, and 2-OH/H*~pro-R~*-29 ([Figure 9](#marinedrugs-16-00038-f009){ref-type="fig"}b). Therefore, the structure of **24**---named xylomolin K~1~---was assigned as 6-hydroxy-1-*O*-deisobutyryl-moluccensin I.

Compound **25** provided the molecular formula C~31~H~36~O~11~ as determined from the positive HRESIMS ion peak at *m*/*z* 607.2164 (calcd. for \[M + Na\]^+^, 607.2150). The NMR spectroscopic data of **25** ([Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}) were similar to those of **24**, except for the replacement of 3-*O*-(2-methyl)butyryl in **24** by an isobutyryloxy group (δ~H~ 2.45 m 1H, 1.11 d (*J* = 6.8 Hz, 3H), 1.11 d (*J* = 6.8 Hz, 3H); δ~C~ 174.8 qC, 34.2 CH, 18.8 CH~3~, 19.0 CH~3~) in **25**. The HMBC correlation from H-3 to the carbonyl carbon (C-32) of the isobutyryloxy group placed it at C-3. The relative configuration of **25** was determined to be the same as that of **24** based on NOE interactions between H-17/H-12β, H-11β/H-5, H-5/H~3~-28, H-12α/H~3~-18, H~3~-18/H-11α, H*~pro-R~*-29/H-3, and H*~pro-S~*-29/H~3~-19. Thus, the structure of **25**---named xylomolin K~2~---was identified as 3-*O*-isobutyryl-3-de(2-methyl)butyryloxy-xylomolin K~1~.

Compound **26** was obtained as an amorphous white powder. Its molecular formula was determined to be C~33~H~38~O~14~ by the positive HRESIMS ion peak at *m*/*z* 681.2149 (calcd. for \[M + Na\]^+^, 681.2154). The NMR spectroscopic data of **26** ([Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}) resembled those of 2-*O*-acetyl-2-dehydroxy-12-deacetylxyloccensin U \[[@B18-marinedrugs-16-00038]\], being a phragmalin 8,9,30-*ortho* ester isolated from *X. moluccensis*, except for the presence of an additional 6-OH group and the absence of the 12-OH group in **26**. The presence of the 6-OH group was supported by the downshifted C-6 signal (δ~C~ 71.5 CH in **26**, whereas δ~C~ 33.7 CH~2~ in 2-*O*-acetyl-2-dehydroxy-12-deacetylxyloccensin U), the ^1^H-^1^H COSY cross-peak between H-5/H-6 and HMBC correlations between H-6/C-5 and H-6/C-7. The upshifted C-12 signal (δ~C~ 29.5, CH~2~ in **26**, whereas δ~C~ 66.6 CH in 2-*O*-acetyl-2-dehydroxy-12-deacetylxyloccensin U), ^1^H-^1^H COSY cross-peaks between H~2~-11/H~2~-12, and HMBC correlations between H~3~-18/C-12 ([Figure 10](#marinedrugs-16-00038-f010){ref-type="fig"}a) confirmed the absence of the 12-OH group in **26**. NOE correlations between H-17/H-12β, H-12β/H-5, H-17/H-5, H-5/H-30, H~3~-18/H-12α, H~3~-18/H-11α, H~3~-19/H*~pro-S~*-29, and H-3/H*~pro-R~*-29 revealed the same relative configuration of **26** as that of 2-*O*-acetyl-2-dehydroxy-12-deacetylxyloccensin U ([Figure 10](#marinedrugs-16-00038-f010){ref-type="fig"}b). The ECD spectrum of **26** was nicely matched with that of 2-*O*-acetyl-2-dehydroxy-12-deacetylxyloccensin U ([Figure 10](#marinedrugs-16-00038-f010){ref-type="fig"}c), revealing the same absolute configuration for the two compounds. Thus, the structure of **26**---named xylomolin L~1~---was assigned as 6-hydroxy-12-dehydroxy-2-*O*-acetyl-2-dehydroxy-12-deacetylxyloccensin U.

The molecular formula of **27** was determined to be C~34~H~40~O~13~ by the positive HRESIMS ion peak at *m*/*z* 679.2374 (calcd. for \[M + Na\]^+^, 679.2361). The NMR spectroscopic data of **27** ([Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}) closely resembled those of swietephragmin G \[[@B26-marinedrugs-16-00038]\], being a phragmalin 8,9,30-*ortho* ester, except for the presence of an additional 12-OH group, which was supported by the downshifted C-12 signal (δ~C~ 66.5 CH in **27**, whereas δ~C~ 29.2 CH~2~ in swietephragmin G), ^1^H-^1^H COSY cross-peaks between H~2~-11/H-12, and HMBC correlations between H~3~-18/C-12. The strong NOE interaction between H-17/H-12 assigned the β-oriented H-12 and the corresponding α-orientation for the 12-OH group. The NOE interaction between H~3~-37/H~3~-38 assigned the *E* configuration for the double bond of 3-tigloyloxy group. Therefore, the structure of **27**---named xylomolin L~2~---was identified as 12α-hydroxy-swietephragmin G.

Compound **28** had the molecular formula C~28~H~37~O~6~ as determined from the positive HRESIMS ion peak at *m*/*z* 469.2603 (calcd. for \[M + H\]^+^, 469.2585). The NMR spectroscopic data of **28** ([Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}) were closely related to those of andirolide Q \[[@B27-marinedrugs-16-00038]\], except for the different positions of the ester carbonyl carbon of the C-17 attached five-membered γ-lactone ring, *viz.* C-21 in **28** instead of C-23 in andirolide Q. Significant ^1^H-^1^H COSY correlations between H-17/H-20, H-20/H~2~-22, H~2~-22/H~2~-23 and the HMBC correlation between H-17/C-21 confirmed the above deduction ([Figure 11](#marinedrugs-16-00038-f011){ref-type="fig"}a). NOE interactions between H-17/H-12β, H-12β/H~3~-30, H~3~-30/H-7, H~3~-30/H-11β, H-11β/H~3~-19, and H~3~-18/H-11α, H~3~-18/H-12α, H~3~-18/H-20, H~3~-18/H-9, and H-9/H-5 indicated the β-orientation for H-7, H-17, H~3~-19, and H~3~-30, and the α-orientation for H-5, H-9, H~3~-18, and H-20 ([Figure 11](#marinedrugs-16-00038-f011){ref-type="fig"}b). Hence, the relative configuration of **28**---named xylomolin M---was assigned as depicted.

Compound **29** afforded the molecular formula C~27~H~34~O~8~ as deduced from the positive HRESIMS ion peak at *m*/*z* 509.2147 (calcd. for \[M + Na\]^+^, 509.2146). The NMR spectroscopic data of **29** ([Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}) closely resembled those of moluccensin O \[[@B25-marinedrugs-16-00038]\], except for the absence of the 21-OH group, which was corroborated by the upshifted C-21 signal (δc 72.4 CH~2~ in **29**, δc 98.1 CH in moluccensin O) and HMBC correlations from H~2~-21 (δ~H~ 4.85 br d (*J* = 18.3 Hz), 5.03 dd (*J* = 18.3, 2.0 Hz)) to C-20 and C-22. The relative configuration of **29** was assigned as the same as that of moluccensin O based on NOE correlations. Thus, the structure of compound **29**---named xylomolin N---was assigned as 21-dehydroxy-moluccensin O.

The antitumor activities of **1**, **3**, **8**, **10**, **11**, **14**--**16**, **20**, **23**, **25**, and **27** were tested by the MTT cytotoxity assay against five human tumor cell lines, including human colorectal HCT-8 and HCT-8/T, human ovarian A2780 and A2780/T, and human breast MD-MBA-231 ([Table S1](#app1-marinedrugs-16-00038){ref-type="app"}) \[[@B28-marinedrugs-16-00038]\]. Cisplatin was used as the positive control. Compounds **11** and **23** showed weak activities against the tested cancer cell lines, whereas the other ten compounds were inactive at 100 μM. Compound **23** exhibited selective antitumor activity against human breast MD-MBA-231 cancer cells with an IC~50~ value of 37.7 μM.

Anti-HIV activities of **1**, **3**, **8**, **10**, **11**, **14**, **20**, **23**--**25**, and **27** were tested in vitro with the HIV-1 virus transfected 293 T cells \[[@B29-marinedrugs-16-00038]\]. At the concentration of 20 μM, **1**, **11**, **23**, and **24** showed inhibitory rates of 17.49 ± 6.93%, 24.47 ± 5.04%, 14.77 ± 5.91%, and 14.34 ± 3.92%, respectively ([Table S2](#app1-marinedrugs-16-00038){ref-type="app"}). Efavirenz was used as the positive control with an inhibitory rate of 88.54 ± 0.45% at the same concentration.

3. Materials and Methods {#sec3-marinedrugs-16-00038}
========================

3.1. General Methods {#sec3dot1-marinedrugs-16-00038}
--------------------

Optical rotations were recorded on a MCP500 modular circular polarimeter (Anton Paar Opto Tec GmbH, Seelze, Germany). UV spectra were obtained on a GENESYS 10S UV-Vis spectrophotometer (Thermo Fisher Scientific, Shanghai, China). HRESIMS were measured on a Bruker maXis ESI-QTOF mass spectrometer (Bruker Daltonics, Bremen, Germany). NMR spectra were recorded on a Bruker AV-400 spectrometer with TMS as the internal standard. Single-crystal X-ray diffraction analyses were made on an Agilent Xcalibur Atlas Gemini Ultra-diffractometer (Agilent Technologies, Santa Clara, CA, USA) with mirror monochromated CuKα radiation (λ = 1.54178 Å) at 150 K. Semi-preparative HPLC (Waters Corporation, Milford, MA, USA) was performed on a Waters 2535 pump equipped with a waters 2998 photodiode array detector and YMC C18 reverse-phased columns (250 mm × 10 mm i.d., 5 μm). For column chromatography, silica gel (100--200 mesh) (Qingdao Mar. Chem. Ind. Co. Ltd., Qingdao, China) and C~18~ reverse-phased silica gel (ODS-A-HG 12 nm, 50 µm, YMC Co. Ltd., Kyoto, Japan) were used. ECD spectra were measured on a Jasco J-810 spectropolarimeter (JASCO Corporation, Tokyo, Japan) in MeCN.

3.2. Plant Material {#sec3dot2-marinedrugs-16-00038}
-------------------

A batch of seeds of *Xylocarpus moluccensis* were collected at the mangrove swamp of Trang Province, Thailand, in June 2013, whereas another batch of seeds of the same mangrove plant were collected in Godavari estuary, Andhra Pradesh, India, in October 2009, respectively. The identification of the plant was performed by one of the authors (J.W.) and Mr. Tirumani Satyanandamurty (Government Degree College at Amadala Valasa, India). Voucher samples (No. ThaiXM-03 and No. IXM200901, respectively) were maintained in the Marine Drugs Research Center, College of Pharmacy, Jinan University.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-16-00038}
-----------------------------

The dried seeds (10.0 kg, ThaiXM-03) of *X. moluccensis* were extracted with 95% (*v*/*v*) EtOH at room temperature (5 × 20 L) to afford the EtOH extract (680.0 g), which was suspended in water and extracted with EtOAc. The resulting EtOAc extract (296.0 g) was chromatographed on silica gel column and eluted with CHCl~3~/MeOH (100:0 to 5:1) to yield 160 fractions.

Fractions 26--28 (31.6 g) were combined and further purified with an RP-18 column (acetone/H~2~O, 50:50 to 100:0) to afford 57 subfractions. Subfraction 23 was purified by preparative HPLC (YMC-Pack ODS-5-A, 250 mm × 10 mm i.d., MeOH/H~2~O, 50:50) to afford compound **1** (45.0 mg).

Fractions 29--40 (111.0 g) were combined and further purified with an RP-18 column (acetone/H~2~O, 50:50 to 100:0) to afford 360 subfractions. The combination of subfractions 90--95 was subjected to preparative HPLC (YMC-Pack ODS-5-A, 250 mm × 10 mm i.d., MeCN/H~2~O, 38:62) to give compound **8** (72 mg), along with five other subfractions (SFr.90-95-1 to SFr.90-95-5). Recrystallization of SFr.90-95-1 afforded compound **20** (15.3 mg). Further purification of SFr.90-95-2 with preparative HPLC (YMC-Pack ODS-5-A, 250 mm × 10 mm i.d., MeOH/MeCN/H~2~O, 10:40:50) yielded compounds **3** (7.1 mg), **5** (4.3 mg), **12** (37 mg), **13** (2.8 mg), and **21** (1.2 mg), whereas that of SFr.90-95-3 with preparative HPLC (YMC-Pack ODS-5-A, 250 mm × 10 mm i.d., MeOH/H~2~O, 60:40 or MeCN/H~2~O, 35:65) afforded compounds **6** (4.3 mg) and **9** (3.1 mg). SFr.90-95-4 was further purified with preparative HPLC (YMC-Pack ODS-5-A, 250 mm × 10 mm i.d., MeCN/H~2~O, 46:64) to afford compound **14** (57.0 mg). Subfractions 78--83 were combined and further purified by preparative HPLC (YMC-Pack ODS-5-A, 250 × 10 mm i.d., MeOH/H~2~O, 50:50) to give compounds **24** (3.5 mg), **26** (2.0 mg), **27** (7.0 mg), and **29** (2.5 mg).

Fractions 157--175 (14.5 g) were combined and further purified with an RP-18 column (acetone/H~2~O, 40:60 to 100:0) to afford 45 subfractions. Subfraction 27 was purified by preparative HPLC (YMC-Pack 250 mm × 10 mm i.d., MeCN/MeOH/H~2~O, 50:15:35) to afford compound **4** (1.2 mg).

The air-dried seeds (15.0 kg, IXM200901) were powdered and extracted with 95% (*v*/*v*) EtOH (5 × 20 L) at room temperature to afford the EtOH extract (1.1 kg), which was partitioned between EtOAc and water to afford the EtOAc portion (572.0 g). Then, 252.0 g of the EtOAc extract was further subjected to a silica gel column (105.0 cm × 9.5 cm i.d.) and eluted with a gradient mixture of CHCl~3~/MeOH (100:1 to 5:1) to afford 184 fractions.

Fractions 38--43 (26.0 g) were combined and further separated on an RP-18 column (64.0 cm × 6.3 cm i.d.), and eluted with a gradient mixture of acetone/H~2~O (40:60 to 100:0) to afford 74 subfractions.

Subfractions 12--16 (1.5 g) were combined and separated by preparative HPLC (YMC-Pack ODS-5-A, 250 mm × 10 mm i.d., MeCN/H~2~O, 36:64) to afford seven parts (SFr.12-16-1 to SFr.12-16-7). SFr.12-16-2 was further purified by preparative HPLC (YMC-Pack ODS-5-A, 250 mm × 10 mm i.d., MeOH/H~2~O, 49:51) to yield compounds **10** (49.3 mg) and **25** (25.7 mg). SFr.12-16-4 and SFr.12-16-5 were further purified by preparative HPLC (YMC-Pack ODS-5-A, 250 mm × 10 mm i.d., MeOH/H~2~O, 52:48) to afford compounds **15** (13 mg) and **22** (3.0 mg), respectively. SFr.12-16-6 was further subjected to preparative HPLC (MeOH/H~2~O, 51:49) to yield compound **2** (2.0 mg), whereas SFr.12-16-7 was further purified by preparative HPLC (MeOH/H~2~O, 60:40, subsequently with MeCN/H~2~O, 60:40, and then MeCN/MeOH/H~2~O, 60:20:20) to yield compound **28** (1.5 mg).

Preparative HPLC (YMC-Pack ODS-5-A, 250 mm × 10 mm i.d., MeOH/H~2~O, 58:42) was performed on subfraction 27 (2.9 g) to gain compound **16** (4.0 mg). Subfractions 32--35 (1.5 g) were combined and separated by preparative HPLC (YMC-Pack ODS-5-A, 250 mm × 10 mm i.d., MeCN/H~2~O, 55:45) to give four parts (SFr.32-35-1 to SFr.32-35-4). SFr.32-35-2 and SFr.32-35-3 were purified by preparative HPLC (MeOH/H~2~O, 65:35, MeOH/H~2~O, 60:40, respectively) to yield compounds **23** (27.0 mg) and **11** (27.5 mg), respectively, whereas recrystallization (acetone) of SFr.32-35-4 afforded compound **7** (23.8 mg).

Fractions 48--86 (43.9 g) were combined and further performed on an RP-18 column (46.7 cm × 6.4 cm i.d.), and eluted with a gradient mixture of MeCN/H~2~O (50:50 to 100:0), to afford 81 subfractions. Subfraction 4 (6.5 g) was purified by preparative HPLC (MeOH/H~2~O, 53:47) to yield compound **17** (5.5 mg). Subfractions 8--14 (10.4 g) were combined and further separated on an RP-18 column (62.0 cm × 6.5 cm i.d.) and eluted with a gradient mixture of acetone/H~2~O (50:50 to 100:0) to afford 37 subsubfractions, among which subsubfractions 12--15 (2.1 g) were combined and separated on the preparative HPLC (MeOH/MeCN/H~2~O, 50:15:35) to give compound **18** (2.1 mg). Subfraction 17 (1.78 g) was subjected to preparative HPLC (MeOH/H~2~O, 80:20) to yield compound **19** (1.2 mg).

Xylomolin A~1~ (**1**): Colorless crystal; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −62.0 (*c* = 0.06, acetone); UV (MeCN) λ~max~ (log ε) 199.7 (3.7) nm; ECD (*c* 0.41 mM, MeCN) λ~max~ (Δε) 190.0 (−12.0), 289.6 (−2.2) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}; HRESIMS *m*/*z* 615.2785 \[M + H\]^+^ (calcd. for C~33~H~43~O~11~, 615.2800).

Xylomolin A~2~ (**2**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −74.7 (*c* 0.04, acetone); UV (MeCN) λ~max~ (log ε) 194.0 (4.5), 279.0 (3.3) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}; HRESIMS *m*/*z* 593.2143 \[M + Cl\]^−^ (calcd. for C~30~H~38~O~10~Cl, 593.2159).

Xylomolin A~3~ (**3**): White, amorphous solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −96.0 (*c* 0.05, acetone); UV (MeCN) λ~max~ (log ε) 198.9 (3.9) nm; ECD (*c* 0.16 mM, MeCN) λ~max~ (Δε) 191.0 (−14.5) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}; HRESIMS *m*/*z* 625.2620 \[M + Na\]^+^ (calcd. for C~32~H~42~NaO~11~, 625.2619).

Xylomolin A~4~ (**4**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −24.0 (*c* 0.08, acetone); UV (MeCN) λ~max~ (log ε) 197.0 (3.9), 201.8 (3.8) nm; ECD (*c* 0.15 mM, MeCN) λ~max~ (Δε) 190(−8.1), 200.4 (−5.0), 211.6 (−6.6) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}; HRESIMS *m*/*z* 683.2675 \[M + Na\]^+^ (calcd. for C~34~H~44~NaO~13~, 683.2674).

Xylomolin A~5~ (**5**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −52.0 (*c* 0.04, acetone); UV (MeCN) λ~max~ (log ε) 201.0 (3.8) nm; ECD (*c* 0.16 mM, MeCN) λ~max~ (Δε) 191.0 (−8.6) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}; HRESIMS *m*/*z* 625.2252 \[M + Na\]^+^ (calcd. for C~31~H~38~NaO~12~, 625.2255).

Xylomolin A~6~ (**6**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −216.0 (*c* 0.10, acetone); UV (MeCN) λ~max~ (log ε) 197.8 (4.0) nm; ECD (*c* 0.16 mM, MeCN) λ~max~ (Δε) 190.0 (−12.8), 216.4 (+1.5), 294.2 (−2.3) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}; HRESIMS *m*/*z* 609.2311 \[M + Na\]^+^ (calcd. for C~31~H~38~NaO~11~, 609.2306).

Xylomolin A~7~ (**7**): White powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −250.7 (*c* 0.08, acetone); UV (MeCN) λ~max~ (log ε) 193.0 (4.5) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 1](#marinedrugs-16-00038-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00038-t002){ref-type="table"}; HRESIMS *m*/*z* 593.2358 \[M + Na\]^+^ (calcd. for C~31~H~38~NaO~10~, 593.2357).

Xylomolin B~1~ (**8**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +212.0 (*c* 0.08, acetone); UV (MeCN) λ~max~ (log ε) 204.0 (3.9), 285.4 (4.0) nm; ECD (*c* 0.10 mM, MeCN) λ~max~ (Δε) 252.1 (−1.6), 278.9 (+8.6) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}; HRESIMS *m*/*z* 607.2151 \[M + Na\]^+^ (calcd. for C~31~H~36~NaO~11~, 607.2150).

Xylomolin B~2~ (**9**): White, amorphous solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +137.0 (*c* 0.10, acetone); UV (MeCN) λ~max~ (log ε) 207.2 (3.7), 285.2 (4.0) nm; ECD (*c* 0.19 mM, MeCN) λ~max~ (Δε) 190.0 (+3.6), 213.7 (−1.1), 282.2 (+9.5) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}; HRESIMS *m*/*z* 527.2273 \[M + H\]^+^ (calcd. for C~29~H~35~O~9~, 527.2276).

Xylomolin C~1~ (**10**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +156.0 (*c* 0.07, acetone); UV (MeCN) λ~max~ (log ε) 191.0 (4.3), 275 (4.1) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}; HRESIMS *m*/*z* 543.2238) \[M + H\]^+^ (calcd. for C~29~H~35~O~10~, 543.2230).

Xylomolin C~2~ (**11**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +125.7 (*c* 0.09, acetone); UV (MeCN) λ~max~ (log ε) 194.0 (4.7), 277 (4.6) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}; HRESIMS *m*/*z* 591.2570 \[M + Na\]^+^ (calcd. for C~32~H~40~NaO~9~, 591.2565).

Xylomolin D (**12**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −34.0 (*c* 0.05, acetone); UV (MeCN) λ~max~ (log ε) 208.2 (3.8) nm; ECD (*c* 0.16 mM, MeCN) λ~max~ (Δε) 190.0 (−2.6), 217.5 (+13.7), 244.5 (−0.3), 261 (+ 1.5), 291.2 (−3.8) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}; HRESIMS *m*/*z* 625.2612 \[M + Na\]^+^ (calcd. for C~32~H~42~NaO~11~, 625.2619).

Xylomolin E (**13**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −68.0 (*c* 0.04, acetone); UV (MeCN) λ~max~ (log ε) 207.2 (3.9) nm; ECD (*c* 0.15 mM, MeCN) λ~max~ (Δε) 190.0 (−9.5), 213.7 (+2.5) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}; HRESIMS *m*/*z* 625.2250 \[M + Na\]^+^ (calcd. for C~31~H~38~NaO~12~, 625.2255).

Xylomolin F (**14**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +4.0 (*c* 0.03, acetone); UV (MeCN) λ~max~ (log ε) 211.0 (4.1) nm; ECD (*c* 0.21 mM, MeCN) λ~max~ (Δε) 192.0 (−7.1), 219.0 (+4.0), 265.0 (+3.2) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 3](#marinedrugs-16-00038-t003){ref-type="table"} and [Table 4](#marinedrugs-16-00038-t004){ref-type="table"}; HRESIMS *m*/*z* 669.2521 \[M + Na\]^+^ (calcd. for C~33~H~42~NaO~13~, 669.2518).

Xylomolin G~1~ (**15**): White, amorphous solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −65.0 (*c* 0.1, acetone); UV (MeCN) λ~max~ (log ε) 190.2 (4.20) nm; ECD (*c* 0.14 mM, MeCN) λ~max~ (Δε) 207 (+2.3), 238 (−3.8), 290 (+1.4), 321 (−0.32), 344 (+0.32) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}; HRESIMS *m*/*z* 587.2494 \[M + H\]^+^ (calcd. for C~31~H~39~O~11~, 587.2492).

Xylomolin G~2~ (**16**): White, amorphous solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −72.0 (*c* 0.05,acetone); UV (MeCN) λ~max~ (log ε) 190.2 (4.03); ECD (*c* 0.13 mM, MeCN) λ~max~ (Δε) 205.0 (+1.7), 239.0 (−4.3), 302.0 (+0.34), 339.0 (+1.1) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}; HRESIMS *m*/*z* 615.2809 \[M + H\]^+^ (calcd. for C~33~H~43~O~11~, 615.2805).

Xylomolin G~3~ (**17**): White, amorphous solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −43.5 (*c* 0.04, acetone); UV (MeCN) λ~max~ (log ε) 196.6 (4.03), 285.0 (2.93) nm; ECD (*c* 0.15 mM, MeCN) λ~max~ (Δε) 193.0 (−4.5), 197.0 (−3.4), 205.0 (−7.5), 216.0 (−5.0), 233.0 (−7.9), 298 (+4.3) nm; ^1^H and^13^C NMR spectroscopic data see [Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}; HRESIMS *m*/*z* 543.2246 \[M + H\]^+^ (calcd. for C~29~H~35~O~10~, 543.2230).

Xylomolin G~4~ (**18**): White, amorphous solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −44.0 (*c* 0.01,acetone); UV (MeCN) λ~max~ (log ε) 196.6 (4.08) nm; ECD (*c* 0.18 mM, MeCN) λ~max~ (Δε) 203.0 (−8.7), 215.0 (−6.2), 233.0 (−10.3), 301.0 (+5.0) nm; ^1^H and^13^C NMR spectroscopic data see [Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}; HRESIMS *m*/*z* 555.2593 \[M + H\]^+^ (calcd. for C~31~H~39~O~9~, 555.2594).

Xylomolin G~5~ (**19**): White, amorphous solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −37.5 (*c* 0.024, acetone); UV (MeCN) λ~max~ (log ε) 195.0 (4.27), 284.2 (2.86) nm; ECD (*c* 0.11 mM, MeCN) λ~max~ (Δε) 195.0 (+ 0.70), 206.0 (−4.9), 214.0 (−3.5), 231.0 (−6.1), 299.0 (+2.7) nm; ^1^H and^13^C NMR spectroscopic data see [Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}; HRESIMS *m*/*z* 569.2753 \[M + H\]^+^ (calcd. for C~32~H~41~O~9~, 569.2751).

Xylomolin H (**20**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +65.0 (*c* 0.06, acetone); UV (MeCN) λ~max~ (log ε) 212.3 (4.0) nm; ECD (c 0.16 mM, MeCN) λ~max~ (Δε) 223 (+10.9), 245 (+0.19),270 (+8.1) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}; HRESIMS *m*/*z* 667.2359 \[M + Na\]^+^ (calcd. for C~33~H~40~NaO~13~, 667.2361).

Xylomolin I (**21**): Light yellow, amorphous gum; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +129.0 (*c* 0.08, acetone); UV (MeCN) λ~max~ (log ε) 208.4 (3.8), 287.6 (4.1) nm; ECD (*c* 0.17 mM, MeCN) λ~max~ (Δε) 200.0 (+4.6), 213.0 (+2.3), 232.0 (+4.6), 259.0 (−3.9), 291.0 (+10.3) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 5](#marinedrugs-16-00038-t005){ref-type="table"} and [Table 6](#marinedrugs-16-00038-t006){ref-type="table"}; HRESIMS *m*/*z* 621.2304 \[M + Na\]^+^ (calcd. for C~32~H~38~NaO~11~, 621.2306)

Xylomolin J~1~ (**22**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −135.0 (*c* 0.11, acetone); UV (MeCN) λ~max~ (log ε) 197.0 (4.9), 213.4 (4.8), 260.8 (4.6) nm; ECD (*c* 0.039 mM, MeCN) λ~max~ (Δε) 204.0 (−3.3), 229.0 (+3.3), 266.0 (+6.3), 310.0 (−0.19), 346.0 (+0.95) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}; HRESIMS *m*/*z* 541.2077 \[M + H\]^+^ (calcd. for C~29~H~33~O~10~, 541.2074).

Xylomolin J~2~ (**23**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +232.0 (*c* 0.1, acetone); UV (MeCN) λ~max~ (log ε) 196.8 (5.2), 211.0 (5.1), 260.8 (5.0) nm; ECD (*c* 0.039 mM, MeCN) λ~max~ (Δε) 190.0 (−3.9), 199.0 (−2.0), 206.0 (−2.9), 225.0 (+3.9), 267.0 (+9.1), 310.0 (−0.17), 335.0 (+1.0) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}; HRESIMS *m*/*z* 583.2548 \[M + H\]^+^ (calcd. for C~32~H~39~O~10~, 583.2543).

Xylomolin K~1~ (**24**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +98.0 (*c* 0.1, acetone); UV (MeCN) λ~max~ (log ε) 194.0 (4.3), 271.0 (4.3) nm; ECD (*c* 0.33 mM, MeCN) λ~max~ (Δε) 209.0 (+3.0), 211.0 (+2.9), 232.0 (+8.5), 275.0 (−2.8), 300.0 (+6.4) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}; HRESIMS *m*/*z* 621.2306 \[M + Na\]^+^ (calcd. for C~32~H~38~NaO~11~, 621.2306).

Xylomolin K~2~ (**25**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +120.4 (*c* 0.07, acetone); UV (MeCN) λ~max~ (log ε) 191.0 (4.3), 272.0 (4.5) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}; HRESIMS *m*/*z* 607.2164 \[M + Na\]^+^ (calcd. for C~31~H~36~NaO~11~, 607.2150).

Xylomolin L~1~ (**26**) : White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +64.0 (*c* 0.09, acetone); UV (MeCN) λ~max~ (log ε) 213.0 (4.0) nm; ECD (*c* 0.30 mM, MeCN) λ~max~ (Δε) 220.0 (+12.5), 249.0 (+ 1.1), 270.0 (+ 0.8), 236.0 (+ 1.9) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}; HRESIMS *m*/*z* 681.2149 \[M + Na\]^+^ (calcd. for C~33~H~38~NaO~14~, 681.2154).

Xylomolin L~2~ (**27**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +42.0 (*c* 0.06, acetone); UV (MeCN) λ~max~ (log ε) 214 (4.5) nm; ECD (*c* 0.15 mM, MeCN) λ~max~ (Δε) 198.0 (+3.2), 213.0 (−3.6), 234.0 (+11.6) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}; HRESIMS *m*/*z* 679.2374 \[M + Na\]^+^ (calcd. for C~34~H~40~NaO~13~, 679.2361).

Xylomolin M (**28**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −252.0 (*c* 0.03, acetone); UV (MeCN) λ~max~ 200.0 (4.0), 232 (4.1) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}; HRESIMS *m*/*z* 469.2603 \[M + H\]^+^ (calcd. for C~28~H~37~O~6~, 469.2585).

Xylomolin N (**29**): White, amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −17.0 (*c* 0.05, acetone); UV (MeCN) λ~max~ (log ε) 196 (3.7), 211 (3.7) nm; ECD (*c* 0.21 mM, MeCN) λ~max~ (Δε) 200.0 (−7.0), 224.0 (+2.1), 252.0 (−0.3) nm; ^1^H and ^13^C NMR spectroscopic data see [Table 7](#marinedrugs-16-00038-t007){ref-type="table"} and [Table 8](#marinedrugs-16-00038-t008){ref-type="table"}; HRESIMS *m*/*z* 509.2147 \[M + Na\]^+^ (calcd. for C~27~H~34~NaO~8~, 509.2146).

3.4. X-ray Crystal Data for Xylomolin A~1~ *(**1**)* {#sec3dot4-marinedrugs-16-00038}
----------------------------------------------------

Orthorhombic, C~34~H~46~O~12~ (C~33~H~42~O~11~·CH~3~OH), space group *P*2(1)2(1)2(1), a = 8.82730 (5) Å, b = 17.93740 (10) Å, c = 20.84108 (13) Å, α = 90°, β = 90°, γ = 90°, V = 3299.95 (3) Å^3^, Z = 4, D~calcd.~ = 1.302 Mg/m^3^, μ = 0.816 mm^−1^. Crystal size: 0.40 × 0.40 × 0.28 mm^3^. 47,329 measured reflections, 5877 \[*R*~int~ = 0.0378\] independent reflections, 426 parameters, 0 restraints, *F*(000) = 1384.0, *R*~1~ = 0.0296, *wR*~2~ = 0.0773(all data), *R*~1~ = 0.0286, *wR*~2~ = 0.0763 \[*I* \> 2σ(*I*)\], and goodness-of-fit (*F*^2^) = 1.065. The absolute structural parameter is −0.06(10), Flack x is −0.14(11), and Hooft y is −0.04(3).

CCDC-1590301 (**1**) contains the supplementary crystallographic data for this paper (excluding structure factors). These data are provided free of charge by The Cambridge Crystallographic Data Centre.

3.5. MTT Cytotoxicity Assay {#sec3dot5-marinedrugs-16-00038}
---------------------------

Compounds **1**, **3**, **8**, **10**, **11**, **14**--**16**, **20**, **23**, **25**, and **27** were evaluated by the MTT method for cytotoxicities against human colorectal HCT-8 and HCT-8/T, ovarian A2780 and A2780/T, and breast MD-MBA-231 cancer cell lines. All cell lines were cultured as adherent monolayers in flasks in DMEM culture medium with 10% fetal bovine serum, benzylpenicillin (50 kU/L), and streptomycin (50 mg/L) at 37 °C in a humidified atmosphere of 5% CO~2~. Cells were collected with trypsin and resuspended in a final concentration of 5 × 10^4^/mL. One hundred microliter aliquots for each cell suspension were distributed evenly into 96-well multiplates (number of cells per well is 5 × 10^3^). Different concentrations of the compounds were added into the designated wells. After 72 h, a 10 μL MTT solution (5 mg/mL) was added to each well, and the plate was further incubated for 4 h, allowing viable cells to reduce the yellow MTT into dark-blue formazan crystals which were dissolved in DMSO 100 μL. The absorbance in individual wells was determined at 490 nm by a microplate reader (Biotek, VT, USA) \[[@B28-marinedrugs-16-00038]\]. The concentrations required to inhibit the growth of cancer cells by 50% (IC~50~ values) were calculated from cytotoxicity curves by Bliss method. The positive control was cisplatin. The IC~50~ values of cisplatin in human colorectal HCT-8 and HCT-8/T, ovarian A2780 and A2780/T, and breast MD-MBA-231, were 15.43, 21.98, 8.54, 9.26, and 6.25 μM, respectively.

3.6. HIV-Inhibitory Bioassay {#sec3dot6-marinedrugs-16-00038}
----------------------------

For the assay, 293 T cells (2 × 10^5^) were co-transfected with 0.6 μg of pNL-Luc-E^−^-Vpu^−^ and 0.4 μg of vesicular stomatitis virus glycoprotein (VSV-G) expression vector pHIT/G. After 48 h, the VSV-G pseudotyped viral supernatant (HIV-1) was harvested by filtration through a 0.45-μm filter and the concentration of viral capsid protein was determined by p24 antigen capture ELISA (Biomerieux, Shanghai, China). SupT1 cells were exposed to VSV-G pseudotyped HIV-1 (multiplicity of infection (MOI) = 1) at 37 °C for 48 h in the absence or presence of the test compounds (**1**, **3**, **8**, **10**, **11**, **14**, **20**, **23**--**25**, and **27**). Efavirenz was used as the positive control. The inhibition rates were determined by using a firefly Luciferase Assay System (Promega, Madison, WI, USA) \[[@B29-marinedrugs-16-00038]\].

4. Conclusions {#sec4-marinedrugs-16-00038}
==============

Twenty-nine new limonoids were isolated from the seeds of the mangrove plant, *Xylocarpus moluccensis*, collected in Thailand and India. The structures of these limonoids, including absolute configurations of ten compounds, *viz.* **1**, **15**--**19**, **21**--**23**, and **26**, were established by HRESIMS, extensive NMR investigations, single-crystal X-ray diffraction analysis conducted with Cu Kα radiation, and the comparison of experimental ECD spectra. Compounds **1**--**14** are mexicanolides, whereas **15**--**21** are khayanolides. Compounds **22** and **23** are unusual limonoids possessing a (*Z*)-bicyclo\[5.2.1\]dec-3-en-8-one motif, while **24** and **25** are 30-ketophragmalins. Compounds **26** and **27** are phragmalin 8,9,30-*ortho* esters, whereas **28** and **29** are azadirone and andirobin derivatives. These results demonstrate that *X. moluccensis* continues to be an abundant resource for the production of novel limonoids with structural diversity. Compound **23** exhibited selective antitumor activity against human triple-negative breast MD-MBA-231 cancer cells with an IC~50~ value of 37.7 μM, whereas compounds **1**, **11**, **23**, and **24** showed inhibitory rates of 17.49 ± 6.93%, 24.47 ± 5.04%, 14.77 ± 5.91%, and 14.34 ± 3.92% against HIV-I virus, respectively, at the concentration of 20 μM.

This work was financially supported by NSFC (U1501221, 31770377, 81661148049, and 81125022), the Pearl River S&T Nova Program of Guangzhou, China (201506010023), the Science and Technology Planning Project of Guangdong Province, China (2013B051000057), and the Fundamental Research Funds for the Central Universities, China (21617474). We thank Tirumani Satyanandamurty (Government Degree College at Amadala Valasa, India) and Patchara Pedpradab (Rajamangala University of Technology Srivijaya, Trang Province, Thailand) for providing the plant materials in this work.

The following are available online at [www.mdpi.com/1660-3397/16/1/38/s1](www.mdpi.com/1660-3397/16/1/38/s1). Table S1: Cytotoxic assay results for compounds against human cancer cells; Table S2: HIV-inhibitory bioassay results for tested compounds; Copies of HRESIMS of compounds **1**--**29**, and 1D and 2D NMR spectra of compounds **1**--**29**.
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![Structures of compounds **1**--**29**.](marinedrugs-16-00038-g001){#marinedrugs-16-00038-f001}

![(**a**) Selected ^1^H-^1^H COSY and HMBC correlations for compound **1** (measured in CDCl~3~); (**b**) Diagnostic NOE interactions for compound **1** (measured in CDCl~3~, crystal structure of X-ray diffraction).](marinedrugs-16-00038-g002){#marinedrugs-16-00038-f002}

![Oak Ridge Thermal-Ellipsoid Plot Program (ORTEP) illustration of the X-ray structure of compound **1**. Ellipsoids are given at the 30% probability level.](marinedrugs-16-00038-g003){#marinedrugs-16-00038-f003}

![Molecular Mechanics, Allinger Force Field version 2 (MM2)-optimized two possible 3D structures for compound **13**. (**a**) The structure with a 14α-OH group; (**b**) The structure with a 14β-OH group.](marinedrugs-16-00038-g004){#marinedrugs-16-00038-f004}

![(**a**) Selected ^1^H-^1^H COSY and HMBC correlations for compound **15** (measured in CDCl~3~); (**b**) Diagnostic NOE interactions for compound **15** (measured in CDCl~3~, MM2-optimized structure).](marinedrugs-16-00038-g005){#marinedrugs-16-00038-f005}

![(**a**) Comparison of the experimental electronic circular dichroism (ECD) spectra of compounds **15**--**19** with that of the known compound, thaixylomolin L, containing a Δ^8,14^ double bonds; (**b**) Comparison of the experimental ECD spectra of compound **21** with that of the known compound, thaixylomolin H, containing Δ^8,9^, Δ^14,15^ conjugated double bonds.](marinedrugs-16-00038-g006){#marinedrugs-16-00038-f006}

![(**a**) Selected ^1^H-^1^H COSY and HMBC correlations for compound **22** (measured in CDCl~3~); (**b**) Diagnostic NOE interactions for compound **22** (measured in CDCl~3~, MM2-optimized structure).](marinedrugs-16-00038-g007){#marinedrugs-16-00038-f007}

![(**a**) Comparison of the experimental ECD spectra of compounds **22**, **23** with that of the known compound, trangmolin F; (**b**) Δδ values (Δδ \[ppm\] = \[δ*~S~* − δ*~R~*\]) obtained for the (6*S*) and (6*R*)-MTPA esters of **23**. MTPA: α-methoxy-α-(trifluoromethyl)phenylacetyl.](marinedrugs-16-00038-g008){#marinedrugs-16-00038-f008}

![(**a**) Selected ^1^H-^1^H COSY and HMBC correlations for compound **24** (measured in CDCl~3~); (**b**) Diagnostic NOE interactions for compound **24** (measured in CDCl~3~, MM2-optimized structure).](marinedrugs-16-00038-g009){#marinedrugs-16-00038-f009}

![(**a**) Selected ^1^H-^1^H COSY and HMBC correlations for compound **26** (measured in CDCl~3~); (**b**) Diagnostic NOE interactions for compound **26** (measured in CDCl~3~, MM2-optimized structure); (**c**) Comparison of the experimental ECD spectrum of compound **26** with that of the known compound, 2-*O*-acetyl-2-dehydroxy-12-deacetylxyloccensin U.](marinedrugs-16-00038-g010){#marinedrugs-16-00038-f010}

![(**a**) Selected ^1^H-^1^H COSY and HMBC correlations for compound **28** (measured in CDCl~3~); (**b**) Diagnostic NOE interactions for compound **28** (measured in CDCl~3~, MM2-optimized structure).](marinedrugs-16-00038-g011){#marinedrugs-16-00038-f011}
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###### 

^1^H NMR spectroscopic data (400 MHz, in CDCl~3~) of compounds **1**--**7** (δ in ppm, *J* in Hz).

  Position   1                     2                     3                     4                 5                     6                     7
  ---------- --------------------- --------------------- --------------------- ----------------- --------------------- --------------------- ----------------------
  3          4.97 s                4.93 s                5.04 s                5.12 s            5.06 s                5.19 s                5.52 s
  5          3.35 s                3.13 s                3.28 s                3.47 s            3.45 s                3.09 s                3.10 br d (10.8)
  6α         5.47 s                4.52 br s             4.54 s                5.44 s            5.47 s                4.52 s                2.32 dd (16.5, 1.6)
  6β                                                                                                                                         2.42 dd (16.5, 10.7)
  9          2.10 br s             2.14 br s             2.46 br s             2.49 br d (6.0)   2.42 br s             2.17 br s             2.08 m
  11α        1.80 m                1.84 m                1.85 m                1.84 m            1.84 m                1.82 m                1.74 m
  11β        1.92m                 1.84 m                1.91 m                1.99 m            1.94 m                1.82 ^1^              1.81 m
  12β        1.81 m                1.72 m                1.74 m                1.86 m            1.85 m                1.71 m                1.75 m
  12α        1.18 m                1.24 m                1.23 m                1.13 m            1.22 m                1.17 m                1.13 m
  15α        3.46 dt (20.8, 2.8)   3.47 dt (20.8, 3.2)   3.64 dd (20.8, 3.2)   5.23 d (2.4)      3.65 dd (20.8, 3.2)   3.51 dt (20.8, 3.2)   3.52 dt (20.8, 2.8)
  15β        3.79 d (20.8)         3.77 d (20.8)         3.85 br d (20.8)                        3.81 br d (20.8)      3.88 br d (20.8)      3.88 d (20.8)
  17         5.58 s                5.53 s                5.50 s                5.50 s            5.57 s                5.56 s                5.73 s
  18         1.05 s                1.03 s                1.09 s                1.06 s            1.12 s                1.05 s                1.09 s
  19         1.27 s                1.52 s                1.51 s                1.26 s            1.26 s                1.49 s                1.23 s
  21         7.52 br d (0.8)       7.47 br d (0.8)       7.50 br s             7.59 t (0.8)      7.57 br s             7.47 br d (0.8)       7.54 br s
  22         6.45 br d (1.2)       6.41 br d (0.8)       6.42 br d (1.2)       6.50 br d (1.2)   6.48 br d (1.2)       6.41 br t (0.8)       6.47 br d (1.2)
  23         7.44 t (1.6)          7.43 t (1.6)          7.44 t (1.6)          7.45 t (1.6)      7.44 t (1.6)          7.43 t (1.6)          7.42 br d (1.6)
  28         0.84 s                0.78 s                0.78 s                0.82 s            0.82 s                0.79 s                0.71 s
  29         1.04 s                1.05 s                1.06 s                1.09 s            1.05 s                1.21 s                0.97 s
  30β        3.23 d (14.4)         3.21 d (14.8)         4.69 s                5.00 s            4.69 s                3.72 d (14.4)         3.47 d (14.8)
  30α        1.79 ^1^              1.78 m                                                                              2.06 br d (14.4)      2.07 ^1^
  7-OMe-31   3.73 s                3.83 s                3.83 br s             3.75 s            3.76 s                3.84 s                3.70 s
  3-OAcyl                                                                                                                                    
  33         2.64 m                2.45 m                2.38 m                2.27 m            2.17 s                2.20 s                2.22 s
                                   2.43 m                                                                                                    
  34         1.22 d (7.2)          1.20 t (7.6)          1.50 m                1.49 m            6-Acyl                2-Acyl                2-Acyl
                                                         1.80 m                1.80 m                                                        
  35         1.24 d (7.2)                                0.99 t (7.2)          0.95 t (7.2)      2.18 s                2.13 s                2.12 s
  36         6-Acyl                                      1.19 d (7.2)          1.20 d (7.2)                                                  
  37         2.19 s                                                            6-Acyl                                                        
  38                                                                           2.18 s                                                        
  2-OH       4.12 br s             4.16 s                4.62 s                4.22 s            4.57 br s                                   
  6-OH                             2.80 br s             2.85 s                                                        2.80 br s             
  15-OH                                                                        3.66 br s                                                     
  30-OH                                                  2.77 br s             2.58 br s         2.67 br s                                   

^1^ Overlapped signals assigned by ^1^H-^1^H COSY, HSQC, and HMBC spectra without designating multiplicity.
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###### 

^13^C NMR spectroscopic data (100 MHz, in CDCl~3~) of compounds **1**--**7** (δ in ppm).

  Position   1            2            3            4            5            6            7
  ---------- ------------ ------------ ------------ ------------ ------------ ------------ ------------
  1          216.7 qC     217.2 qC     213.8 qC     212.7 qC     213.1 qC     209.4 qC     209.6 qC
  2          78.0 qC      77.8 qC      79.4 qC      79.3 qC      79.5 qC      85.6 qC      85.8 qC
  3          86.1 CH      86.7 CH      86.3 CH      85.2 CH      86.4 CH      83.4 CH      81.3 CH
  4          39.7 qC      39.5 qC      39.9 qC      39.9 qC      39.8 qC      40.4 qC      40.1 qC
  5          44.2 CH      45.1 CH      45.7 CH      44.7 CH      44.8 CH      44.7 CH      40.7 CH
  6          72.7 CH      73.1 CH      73.0 CH      72.6 CH      72.7 CH      73.2 CH      33.3 CH~2~
  7          171.1 qC     175.2 qC     175.1 qC     171.5 qC     171.2 qC     175.2 qC     174.1 qC
  8          125.7 qC     126.6 qC     128.6 qC     135.4 qC     127.6 qC     126.2 qC     125.5 qC
  9          52.9 CH      53.3 CH      47.4 CH      46.0 CH      46.9 CH      53.1 CH      52.3 CH
  10         52.4 qC      52.4 qC      51.8 qC      52.5 qC      51.9 qC      53.4 qC      53.2 qC
  11         18.7 CH~2~   18.9 CH~2~   18.4 CH~2~   17.9 CH~2~   18.2 CH~2~   18.9 CH~2~   18.7 CH~2~
  12         29.4 CH~2~   29.6 CH~2~   29.1 CH~2~   27.8 CH~2~   28.8 CH~2~   29.5 CH~2~   29.1 CH~2~
  13         38.3 qC      38.2 qC      38.5 qC      39.4 qC      38.6 qC      38.2 qC      38.3 qC
  14         133.5 qC     132.6 qC     137.8 qC     140.1 qC     138.5 qC     133.2 qC     133.4 qC
  15         33.4 CH~2~   33.6 CH~2~   32.8 CH~2~   65.4 CH      32.8 CH~2~   33.6 CH~2~   33.5 CH~2~
  16         169.2 qC     169.3 qC     168.9 qC     173.6 qC     169.2 qC     169.3 qC     169.9 qC
  17         80.8 CH      80.8 CH      80.7 CH      81.1 CH      80.6 CH      80.6 CH      80.3 CH
  18         18.0 CH~3~   18.3 CH~3~   17.7 CH~3~   16.1 CH~3~   17.6 CH~3~   18.4 CH~3~   18.1 CH~3~
  19         16.7 CH~3~   17.6 CH~3~   17.6 CH~3~   17.0 CH~3~   16.8 CH~3~   17.8 CH~3~   16.9 CH~3~
  20         120.5 qC     120.6 qC     120.5 qC     119.8 qC     120.3 qC     120.6 qC     120.5 qC
  21         141.5 CH     141.1 CH     141.2 CH     141.9 CH     141.7 CH     141.2 CH     141.8 CH
  22         109.8 CH     109.7 CH     109.7 CH     109.8 CH     109.9 CH     109.7 CH     109.9 CH
  23         143.1 CH     143.2 CH     143.2 CH     143.2 CH     143.1 CH     143.2 CH     142.9 CH
  28         22.5 CH~3~   22.6 CH~3~   22.8 CH~3~   22.5 CH~3~   22.7 CH~3~   22.6 CH~3~   22.8 CH~3~
  29         22.7 CH~3~   22.6 CH~3~   22.7 CH~3~   22.7 CH~3~   22.6 CH~3~   23.5 CH~3~   21.1 CH~3~
  30         44.4 CH~2~   44.6 CH~2~   73.0 CH      73.6 CH      72.9 CH      40.1 CH~2~   40.3 CH~2~
  31         53.2 CH~3~   53.2 CH~3~   53.3 CH~3~   53.3 CH~3~   53.3 CH~3~   53.3 CH~3~   52.2 CH~3~
             3-Acyl       3-Acyl       3-Acyl       3-Acyl       3-Acyl       3-Acyl       3-Acyl
  32         175.9 qC     173.3 qC     175.5 qC     175.3 qC     169.7 qC     169.6 qC     169.6 qC
  33         34.5 CH      28.0 CH~2~   41.2 CH      41.8 CH      21.2 CH~3~   21.2 CH~3~   21.3 CH~3~
                                                                 6-Acyl       2-Acyl       2-Acyl
  34         19.9 CH~3~   9.4 CH~3~    26.1 CH~2~   26.5 CH~2~   169.7 qC     169.1 qC     169.0 qC
  35         18.4 CH~3~                11.6 CH~3~   11.8 CH~3~   21.0 CH~3~   21.8 CH~3~   21.7 CH~3~
  36                                   17.5 CH~3~   17.5 CH~3~                             
             6-Acyl                                 6-Acyl                                 
  37         169.7 qC                               169.8 qC                               
  38         21.0 CH~3~                             21.0 CH~3~                             
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###### 

^1^H NMR spectroscopic data (400 MHz) of compounds **8**--**14** (δ in ppm, *J* in Hz).

  Position   8 ^1^              9 ^1^              10 ^1^                11 ^1^               12 ^2^            13 ^1^          14 ^1^
  ---------- ------------------ ------------------ --------------------- -------------------- ----------------- --------------- -----------------
  2                             3.02 t (6.0)                                                                                    
  3          5.51 s             4.26 d (6.0)       4.83 s                4.99 s               4.55 s            4.76 s          4.55 s
  5          2.98 s             2.94 br s          3.12 s                3.20 dd (9.2, 3.2)   3.22 s            3.49 s          2.67 s
  6          5.51 s             5.47 s             4.38 s                2.32 m               4.40 d (4.8)      5.55 s          4.20 br s
                                                                         2.35 m                                                 
  9                                                2.29 dt (12.4, 2.8)   2.29 m               1.71 t (13.2)     2.81 m          2.30 ^3^
  11α        2.38 m             2.35 m             1.84 m                1.77 m               1.68 m            1.78 m          1.83 m
  11β        2.38 ^3^           2.35 ^3^           1.38 qd (12.8, 4.4)   1.56 m               1.33 m            2.18 m          2.30 m
  12β        1.46 m             1.45 m             2.00 m                1.93 m               1.85 d (14.0)     1.44 m          1.95 m
  12α        1.65 m             1.61 m             1.24 td (13.6, 4.4)   1.29 m               1.19 m            2.05 m          1.41 m
  15α        5.90 s             5.89 s             6.28 s                6.32 s               5.99 s            2.93 d (18.0)   6.08 s
  15β                                                                                                           3.05 d (18.0)   
  17         5.10 s             5.09 s             5.12 s                5.16 s               5.25 s            5.61 s          4.84 s
  18         1.01 s             1.00 s             1.06 s                1.06 s               1.16 s            1.05 s          1.24 s
  19         1.30 s             1.17 s             1.54 s                1.28 s               1.29 s            1.28 s          1.43 s
  21         7.50 br s          7.49 br s          7.52 br s             7.51 br s            7.85 br s         7.76 br s       7.48 br t (0.8)
  22         6.45 br d (1.2)    6.45 br d (1.2)    6.50 br d (1.2)       6.49 br d (1.2)      6.60 br d (1.2)   6.48 br s       6.42 br d (1.2)
  23         7.46 t (1.6)       7.45 t (1.6)       7.45 t (1.6)          7.44 t (1.6)         7.70 t (1.6)      7.45 br s       7.42 t (1.6)
  28         1.20 s             1.17 s             0.81 s                0.74 s               0.69 s            0.92 s          0.84 s
  29         1.01 s             1.13 s             1.09 s                0.82 s               1.04 s            1.07 s          1.59 s
  30β        3.55 d (17.6)      3.29 d (17.6)      6.29 d (4.4)          6.31 d (4.4)         3.38 d (15.6)     5.60 d (2.0)    5.49 s
  30α        2.42 br d (17.6)   2.52 br d (17.6)                                              2.31 d (15.6)                     
  31         3.74 s             3.75 s             3.84 s                3.69 s               3.65 s            3.73 s          3.88 s
             3-Acyl             6-Acyl             3-Acyl                3-Acyl               3-Acyl            3-Acyl          3-Acyl
  33         2.21 s             2.07 s             2.22 s                2.57 m               2.54 m            2.11 s          2.02 s
  34         6-Acyl                                                      1.61 m               1.60 m            6-Acyl          30-Acyl
                                                                         1.81 m               1.54 m                            
  35         2.11 s                                                      1.04 t (7.2)         0.93 t (7.2)      2.19 s          2.59 m
  36                                                                     1.25 d (6.8)         1.12 d (6.8)                      1.13 d (6.8)
  37                                                                                                                            1.17 d (6.8)
  1-OH                                                                                                                          4.55 ^3^
  2-OH                                             4.07 br s                                  5.08 s            4.17 br s       4.11 br s
  6-OH                                             2.97 br s                                  5.58 d (4.8)                      2.93 s
  8-OH                                                                                        5.05 s                            

^1^ Recorded in CDCl~3~; ^2^ Recorded in DMSO-*d*~6~; ^3^ Overlapped signals assigned by ^1^H-^1^H COSY, HSQC, and HMBC spectra without designating multiplicity.
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###### 

^13^C NMR spectroscopic data (100 MHz) of compounds **8**--**14** (δ in ppm).

  Position   8 ^1^        9 ^1^        10 ^1^       11 ^1^       12 ^2^        13 ^1^       14 ^1^
  ---------- ------------ ------------ ------------ ------------ ------------- ------------ ------------
  1          211.1 qC     212.5 qC     212.0 qC     212.7 qC     215.9 qC      213.9 qC     108.4 qC
  2          76.9 qC      50.5 CH      77.5 qC      77.4 qC      76.2 qC       76.9 qC      81.1 qC
  3          81.6 CH      76.7 CH      87.2 CH      85.5 CH      86.5 CH       85.8 CH      85.6 CH
  4          39.6 qC      39.7 qC      39.9 qC      39.7 qC      39.5 qC       39.4 qC      38.8 qC
  5          55.0 CH      55.4 CH      44.8 CH      40.8 CH      44.6 CH       44.8 CH      44.6 CH
  6          69.8 CH      70.2 CH      72.0 CH      32.7 CH~2~   71.2 CH       72.4 CH      71.7 CH
  7          170.6 qC     170.9 qC     175.5 qC     173.5 qC     175.7 qC      171.0 qC     175.9 qC
  8          126.1 qC     127.1 qC     134.7 qC     134.1 qC     71.3 qC       138.8 qC     80.0 qC
  9          148.4 qC     150.3 qC     55.3 CH      53.8 CH      61.6 CH       53.3 CH      51.5 CH
  10         51.9 qC      51.2 qC      53.2 qC      52.6 qC      48.4 qC       49.8 qC      43.1 qC
  11         22.3 CH~2~   22.2 CH~2~   22.5 CH~2~   21.5 CH~2~   20.7 CH~2~    20.3 CH~2~   15.6 CH~2~
  12         29.7 CH~2~   29.7 CH~2~   33.3 CH~2~   32.4 CH~2~   32.5 CH~2~    28.3 CH~2~   25.2 CH~2~
  13         36.8 qC      36.8 qC      37.6 qC      37.5 qC      37.8 qC       41.0 qC      38.8 qC
  14         156.4 qC     157.4 qC     160.7 qC     160.0 qC     168.3 qC      72.9 qC      158.3 qC
  15         111.6 CH     110.6 CH     113.4 CH     113.2 CH     114.6 CH~2~   38.9 CH~2~   118.4 CH
  16         165.2 qC     165.7 qC     164.8 qC     164.6 qC     164.3 qC      168.4 qC     163.1 qC
  17         80.6 CH      80.7 CH      79.7 CH      79.7 CH      78.5 CH       77.2 CH      81.4 CH
  18         16.2 CH~3~   16.1 CH~3~   22.5 CH~3~   21.9 CH~3~   22.6 CH~3~    15.7 CH~3~   19.5 CH~3~
  19         18.2 CH~3~   18.3 CH~3~   16.2 CH~3~   15.6 CH~3~   18.5 CH~3~    15.7 CH~3~   22.1 CH~3~
  20         119.8 qC     119.9 qC     120.0 qC     120.1 qC     120.0 qC      120.1 qC     119.9 qC
  21         141.2 CH     141.2 CH     141.4 CH     141.5 CH     142.3 CH      141.7 CH     141.3 CH
  22         109.9 CH     110.0 CH     110.2 CH     110.2 CH     110.6 CH      109.8 CH     109.9 CH
  23         143.2 CH     143.1 CH     143.3 CH     143.2 CH     143.2 CH      143.1 CH     143.0 CH
  28         26.3 CH~3~   25.6 CH~3~   21.4 CH~3~   21.5 CH~3~   21.7 CH~3~    22.0 CH~3~   24.0 CH~3~
  29         28.0 CH~3~   28.3 CH~3~   23.0 CH~3~   20.8 CH~3~   24.8 CH~3~    22.1 CH~3~   24.5 CH~3~
  30         39.2 CH~2~   28.8 CH~2~   133.5 CH     133.0 CH     45.9 CH~2~    130.2 CH     74.9 CH
  31         53.0 CH~3~   52.8 CH~3~   53.4 CH~3~   52.1 CH~3~   52.0 CH~3~    53.4 CH~3~   53.4 CH~3~
             3-Acyl       6-Acyl       3-Acyl       3-Acyl       3-Acyl        3-Acyl       3-Acyl
  32         170.2 qC     169.2 qC     169.9 qC     176.0 qC     174.7 qC      170.7 qC     171.5 qC
  33         20.9 CH~3~   20.5 CH~3~   20.7 CH~3~   41.4 CH      40.4 CH       20.4 CH      20.7 CH~3~
             6-Acyl                                                            6-Acyl       30-Acyl
  34         169.1 qC                               26.9 CH~2~   26.4 CH       169.6 qC     176.0 qC
  35         20.5 CH~3~                             11.9 CH~3~   11.2 CH~3~    21.0 CH~3~   34.2 CH
  36                                                17.0 CH~3~   16.5 CH~3~                 19.0 CH~3~
  37                                                                                        19.1 CH~3~

^1^ Recorded in CDCl~3~; ^2^ Recorded in DMSO-*d*~6~.
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###### 

^1^H NMR spectroscopic data (400 MHz) of compounds **15**--**21** (δ in ppm, *J* in Hz).

  Position      15 ^1^                16 ^1^               17 ^1^                18 ^1^                      19 ^1^                      20 ^2^               21 ^1^
  ------------- --------------------- -------------------- --------------------- --------------------------- --------------------------- -------------------- ---------------------
  2                                                                                                                                                           5.77 s
  3             4.87 s                4.86 s               4.94 s                5.01 s                      5.02 s                      4.97 s               
  5             2.24 br s             2.22 s               2.13 ^3^              2.24 dd (11.2, 2.4)         2.26 ^3^                    2.87 s               2.19 br s
  6             4.36 br s             4.37 br d (1.6)      4.33 s                2.27 dd (16.0, 2.8)         2.28 dd (16.0, 2.8)         4.83 br d (3.6)      4.42 s
                                                                                 2.43 dd (16.0, 11.2)        2.43 dd (16.0, 11.2)                             
  9             2.52 m                2.51 m               2.51 m                2.45 m                      2.46 m                      2.49 dd (6.4, 2.8)   
  11α           1.81 m                1.80 m               1.84 m                1.77 m                      1.79 m                      2.20 ^3^             2.25 m
  11β           1.40 m                1.40 m               1.40 m                1.46 m                      1.48 m                      2.07 m               2.03 dd (18.8, 4.0)
  12β           1.58 m                1.53 m               1.60 m                1.54 m                      1.55 m                      1.76 m               1.36 m
  12α           1.43 m                1.43 m               1.47 m                1.43 m                      1.44 m                      1.27 m               1.51 overlapped
  15α           3.71 ^3^              3.73 dd (20.0,3.2)   3.43 dd (19.2, 1.6)   3.43 br d (18.4)            3.43 dd (19.6, 1.2)         5.72 br s            6.55 s
  15β           4.07 dd (20.0, 2.8)   4.09 dd (20.0,3.2)   3.98 dd (19.2, 3.2)   3.94 ddd (19.6, 3.6, 2.0)   3.93 ddd (19.6, 3.6, 2.0)                        
  17            5.13 s                5.06 s               5.18 s                5.17 s                      5.14 s                      5.66 s               5.09 s
  18            1.05 s                1.04 s               1.04 s                1.01 s                      1.01 s                      1.38 s               1.00 s
  19            1.34 s                1.34 s               1.29 s                1.01 s                      1.01 s                      1.45 s               1.33 s
  21            7.45 br s             7.43 br s            7.46 s                7.47 br s                   7.47 br s                   7.64 br s            7.49 br s
  22            6.41 br d (1.2)       6.41 br d (0.8)      6.43 br d (0.8)       6.43 br d (1.2)             6.43 br d (0.8)             6.58 br d (1.2)      6.45 br d (1.2)
  23            7.43 t (1.6)          7.42 t (1.6)         7.43 t (1.6)          7.42 t (1.6)                7.42 t (1.6)                7.60 t (1.6)         7.44 t (1.6)
  28            1.19 s                1.20 s               1.20 s                1.00 s                      0.99 s                      1.01 s               1.13 s
  29*~pro-R~*   1.77 d (13.2)         1.80 d (12.8)        1.97 d (12.6)         1.99 d (12.8)               1.98 d (12.4)               2.21 d (11.2)        2.35 d (12.8)
  29*~pro-S~*   2.43 d (13.2)         2.45 d (12.8)        2.31 d (12.6)         2.15 d (12.8)               2.15 d (12.4)               2.88 d (11.2)        2.70 d (12.4)
  30                                                       3.46 br s             3.44 br s                   3.45 br s                                        
  31            3.86 s                3.85 s               3.87 s                3.67 s                      3.67 s                      3.80 s               3.86 s
                3-Acyl                3-Acyl               3-Acyl                3-Acyl                      3-Acyl                      3-Acyl               2-Acyl
  33            2.15 s                2.57 m               2.13 s                2.66 m                      2.47 m                      1.94 s               2.42 m
                30-Acyl                                                                                                                                       
  34            3.50 m                1.20 d (7.2)                               1.21 d (6.8)                1.73 m                      1-Acyl               1.48 m
                3.69 m                                                                                       1.52 m                                           1.73 m
  35            1.27 t (6.8)          1.22 d (7.2)                               1.19 d (7.2)                0.94 t (7.2)                2.55 m               0.97 t (7.6)
                                      30-Acyl                                                                                                                 
  36                                  3.51 m                                                                 1.17 d (7.2)                1.11 d (7.2)         1.22 d (7.2)
                                      3.67 m                                                                                                                  
  37                                  1.27 t (6.8)                                                           5.08 s                      1.10 d (7.2)         
  1-OH          2.91 br s             2.85 s                                                                                                                  2.74 s
  6-OH          2.92 d (3.2)          2.88 d (3.2)         2.94 br d (2.7)                                   5.58 d (4.8)                4.69 br d (3.6)      3.19 s
  8-OH                                                                                                       5.05 s                      5.00 s               
  30-OH                                                                                                                                  4.87 s               3.43 s

^1^ Recorded in CDCl~3~; ^2^ Recorded in acetone-*d*~6~; ^3^ Overlapped signals assigned by ^1^H-^1^H COSY, HSQC, and HMBC spectra without designating multiplicity.

marinedrugs-16-00038-t006_Table 6

###### 

^13^C NMR spectroscopic data (100 MHz) of compounds **15**--**21** (δ in ppm).

  Position   15 ^1^       16 ^1^       17 ^1^       18 ^1^       19 ^2^       20 ^1^       21 ^1^
  ---------- ------------ ------------ ------------ ------------ ------------ ------------ ------------
  1          84.5 qC      84.3 qC      85.2 qC      84.8 qC      84.8 qC      92.6 qC      85.5 qC
  2          204.3 qC     204.1 qC     204.3 qC     204.1 qC     203.9 qC     209.1 qC     82.4 CH
  3          84.8 CH      84.7 CH      85.0 CH      83.3 CH      83.0 CH      90.6 CH      207.8 qC
  4          40.6 qC      40.6 qC      41.2 qC      40.6 qC      40.5 qC      45.1 qC      52.8 qC
  5          45.4 CH      45.5 CH      46.0 CH      40.7 CH      40.5 CH      43.4 CH      51.4 CH
  6          72.0 CH      72.1 CH      71.9 CH      34.2 CH~2~   34.2 CH~2~   71.9 CH      71.0 CH
  7          175.3 qC     175.3 qC     175.4 qC     172.7 qC     172.7 qC     176.2 qC     175.2 qC
  8          134.9 qC     135.0 qC     135.2 qC     134.5 qC     134.4 qC     76.8 qC      130.4 qC
  9          48.3 CH      48.1 CH      49.4 CH      47.9 CH      48.0 CH      48.4 CH      156.6 qC
  10         55.9 qC      56.0 qC      57.0 qC      56.4 qC      56.4 qC      48.0 qC      58.8 qC
  11         19.5 CH~2~   19.5 CH~2~   20.2 CH~2~   19.4 CH~2~   19.4 CH~2~   17.8 CH~2~   20.2 CH~2~
  12         31.9 CH~2~   32.0 CH~2~   32.2 CH~2~   31.9 CH~2~   31.9 CH~2~   29.5 CH~2~   30.0 CH~2~
  13         40.7 qC      40.7 qC      40.4 qC      40.5 qC      40.6 qC      38.7 qC      37.8 qC
  14         138.4 qC     138.5 qC     132.5 qC     133.0 qC     133.0 qC     160.0 qC     154.9 qC
  15         33.1 CH~2~   33.0 CH~2~   35.4 CH~2~   35.4 CH~2~   35.3 CH~2~   120.2 CH     113.4 CH
  16         169.6 qC     169.9 qC     169.8 qC     170.3 qC     170.3 qC     164.9 qC     165.7 qC
  17         80.5 CH      80.5 CH      80.8 CH      80.7 CH      80.7 CH      81.2 CH      80.4 CH
  18         17.7 CH~3~   17.4 CH~3~   17.5 CH~3~   16.8 CH~3~   16.8 CH~3~   21.4 CH~3~   16.2 CH~3~
  19         17.0 CH~3~   17.1 CH~3~   16.7 CH~3~   14.9 CH~3~   14.9 CH~3~   22.2 CH~3~   15.7 CH~3~
  20         120.6 qC     120.6 qC     120.6 qC     120.5 qC     120.5 qC     121.1 qC     120.3 qC
  21         141.1 CH     141.1 CH     141.1 CH     141.2 CH     141.1 CH     142.7 CH     141.2 CH
  22         110.0 CH     110.0 CH     110.1 CH     110.1 CH     110.1 CH     111.1 CH     110.1 CH
  23         143.1 CH     143.1 CH     143.0 CH     142.9 CH     142.9 CH     144.0 CH     143.0 CH
  28         19.8 CH~3~   19.7 CH~3~   19.5 CH~3~   19.2 CH~3~   19.2 CH~3~   15.7 CH~3~   16.3 CH~3~
  29         44.7 CH~2~   44.9 CH~2~   45.4 CH~2~   44.6 CH~2~   44.5 CH~2~   41.5 CH~2~   39.3 CH~2~
  30         92.2 qC      92.3 qC      63.0 CH      63.4CH       63.5 CH      83.6 qC      82.4 qC
  31         53.2 CH~3~   53.1 CH~3~   53.3 CH~3~   51.8 CH~3~   51.7 CH~3~   53.0 CH~3~   53.3 CH~3~
             3-Acyl       3-Acyl       3-Acyl       3-Acyl       3-Acyl       3-Acyl       2-Acyl
  32         169.9 qC     176.0 qC     170.1 qC     176.5 qC     176.0 qC     170.1 qC     176.0 qC
  33         20.6 CH~3~   33.8 CH      20.7 CH~3~   33.9 CH      40.8 CH      21.3 CH~3~   41.3 CH
             30-Acyl                                                          1-Acyl       
  34         63.3 CH~2~   19.0 CH~3~                18.9 CH~3~   26.7 CH~2~   176.0 qC     26.5 CH~2~
  35         15.7 CH~3~   19.1 CH~3~                18.9CH~3~    11.5 CH~3~   35.1 CH      11.7 CH~3~
                          30-Acyl                                                          
  36                      63.4 CH~2~                17.0 CH~3~   16.5 CH~3~   19.4 CH~3~   17.2 CH~3~
  37                      15.7 CH~3~                                          19.3 CH~3~   

^1^ Recorded in CDCl~3~; ^2^ Recorded in acetone-*d*~6~.
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###### 

^1^H NMR spectroscopic data (400 MHz, in CDCl~3~) of compounds **22**--**29** (δ in ppm, *J* in Hz).

  Position      22                23                 24                    25                    26                 27                     28                          29
  ------------- ----------------- ------------------ --------------------- --------------------- ------------------ ---------------------- --------------------------- ----------------------
  1                                                                                                                                        7.14 d (10.4)               3.52 m
  2β                                                                                                                                       5.90 d (10.4)               2.92 dd (14.4,6.4)
  2α                                                                                                                                                                   2.46 dd (14.4,3.6)
  3             5.54 s            5.50 s             4.88 s                4.86 s                5.17 s             4.82 s                                             
  5             2.92 s            2.94 s             2.80 br s             2.82 s                2.40 s             2.37 d (13.6)          2.22 dd (12.4, 2.8)         2.82 d (10.4)
  6a            4.26 br s         4.27 br s          4.58 s                4.58 s                4.51 s             2.40 br d (23.2)       1.93 m (α)                  2.24 d (16.4)
  6b                                                                                                                2.42 dd (23.2, 13.6)   1.99 m (β)                  2.62 dd (16.4, 10.4)
  7                                                                                                                                        5.30 t (2.8)                
  9             3.23 m            3.25 m                                                                                                   2.54 m                      2.22 m
  11α           1.89 m            1.88 m             2.63 m                2.62 m                1.94 m             1.98 t (14.4)          2.10 m                      1.65 m
  11β           1.75 m            1.74 m             2.37 m                2.37 dd (20.0, 3.6)   2.26 m             2.19 dd (14.4, 4.0)    1.83 m                      2.30 m
  12β           1.83 m            1.83 m             1.39 m                1.40 td (12.8, 4.8)   1.56 m             3.87 br d (13.6)       1.70 m                      1.96 m
  12α           1.25 m            1.24 m             1.72 m                1.72 dd (12.8, 4.0)   1.25 m                                    2.20 m                      1.35 dd (17.2, 4.4)
  15α           6.00 s            5.99 s             7.23 s                7.18 s                6.56 s             6.00 s                 5.87 s                      2.86 d (18.0)
  15β                                                                                                                                                                  2.60 d (18.0)
  17            5.33 s            5.34 s             5.01 s                5.01 s                5.61 s             5.80 s                 2.53 overlapped             5.66 s
  18            1.08 s            1.07 s             1.04 s                1.04 s                1.38 s             1.43 s                 1.43 s                      0.93 s
  19            1.21 s            1.22 s             1.54 s                1.54 s                1.54 s             1.33 s                 1.24 s                      0.97 s
  20                                                                                                                                       2.97 ddd (12.0, 9.2, 2.8)   
  21α           7.53 br s         7.53 br s          7.51 br s             7.51 s                7.45 br s          7.67 br s                                          4.85 br d (18.3)
  21β                                                                                                                                                                  5.03 dd (18.3, 2.0)
  22α           6.49 d (1.2)      6.49 d (1.2)       6.48 br d (1.2)       6.47 br d (1.2)       6.41 br s          6.61 br s              2.44 m                      6.08 br s
  22β                                                                                                                                      2.49 m                      
  23α           7.47 t (1.6)      7.47 t (1.6)       7.46 t (1.6)          7.45 t (1.6)          7.43 br s          7.53 br s              4.23 ddd (10.4, 9.2, 6.8)   
  23β                                                                                                                                      4.46 td (8.8, 2.0)          
  28            1.21 s            1.22 s             1.00 s                1.00 s                0.87 s             0.82 s                 1.10 s                      1.03 s
  29*~pro-R~*   2.49 d (19.2)     2.46 br d (18.8)   1.81 dd (10.8, 2.0)   1.81 dd (10.4, 2.0)   1.67 br d (11.0)   1.80 d (11.2)          1.09 s                      1.20 s
  29*~pro-S~*   2.56 d (19.2)     2.58 d (18.8)      2.71 d (10.8)         2.70 d (10.4)         2.36 d (11.0)      1.86 d (11.2)                                      
  30α           6.59 br d (1.6)   6.56 br d (1.6)                                                5.34 s             4.49 s                 1.29 s                      4.92 s (30a)
  30β                                                                                                                                                                  5.22 s (30b)
  31            3.81 s            3.81 s             3.81 s                3.82 s                3.80 s             3.76 s                 7-Acyl                      3.73 s
  32            3-Acyl            3-Acyl             3-Acyl                3-Acyl                                                          1.97 s                      
  33            2.17 s            2.51 m             2.27 m                2.45 m                1.70 s             1.68 s                                             
  34                              1.53 m             1.42 m                                      3-Acyl             3-Acyl                                             
                                  1.74 m             1.58 m                                                                                                            
  35                              0.96 t (7.2)       0.87 t (7.6)          1.11 d (6.8)          2.07 s                                                                
  36                              1.18 d (7.2)       1.07 d (6.8)          1.11 d (6.8)          2-Acyl             6.88 q (6.8)                                       
  37                                                                                             2.17 s             1.73 br d (6.8)                                    
  38                                                                                                                1.84 s                                             
  1-OH                                               2.81 s                2.84 br s                                3.45 s                                             
  2-OH                                               4.93 s                4.93 br s                                3.57 s                                             
  6-OH          3.01 s            3.06 br s          3.12 br s             3.13 s                                                                                      
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###### 

^13^C NMR spectroscopic data (100 MHz, in CDCl~3~.) of compounds **22**--**29** (δ in ppm).

  Position   22           23           24           25           26           27           28           29
  ---------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ -------------
  1          215.1 qC     215.4 qC     85.8 qC      85.9 qC      84.4 qC      84.4 qC      156.7 CH     77.5 CH
  2          193.6 qC     193.5 qC     80.7 qC      80.8 qC      84.0 qC      75.7 qC      126.0 CH     39.2 CH~2~
  3          82.9 CH      82.4 CH      87.2 CH      87.2 CH      85.6 CH      86.6 CH      204.0 qC     212.4 qC
  4          41.1 qC      41.2 qC      45.6 qC      45.6 qC      44.4 qC      43.7 qC      44.1 qC      48.1 qC
  5          49.2 CH      49.2 CH      48.2 CH      48.1 CH      44.8 CH      40.5 CH      46.2 CH      42.9 CH
  6          70.9 CH      70.9 CH      71.5 CH      71.5 CH      71.5 CH      33.8 CH~2~   23.5 CH~2~   32.6 CH~2~
  7          175.1 qC     175.2 qC     175.0 qC     174.9 qC     174.1 qC     174.1 qC     73.9 CH      173.7 qC
  8          149.7 qC     149.6 qC     121.0 qC     121.1 qC     84.0 qC      83.7 qC      44.8 qC      144.8 qC
  9          43.7 CH      44.1 CH      169.8 qC     169.7 qC     86.8 qC      87.1 qC      37.8 CH      49.6 CH
  10         52.7 qC      52.6 qC      48.8 qC      48.8 qC      49.0 qC      47.4 qC      39.9 qC      44.0 qC
  11         21.0 CH~2~   21.2 CH~2~   25.6 CH~2~   25.6 CH~2~   26.3 CH~2~   34.3 CH~2~   15.8 CH~2~   23.7 CH~2~
  12         30.8 CH~2~   30.8 CH~2~   30.1 CH~2~   30.1 CH~2~   29.5 CH~2~   66.5 CH      31.5 CH~2~   29.2 CH~2~
  13         40.0 qC      40.0 qC      36.5 qC      36.5 qC      38.1 qC      44.7 qC      47.9 qC      41.8 qC
  14         165.9 qC     166.2 qC     152.1 qC     152.2 qC     154.6 qC     152.3 qC     193.6 qC     80.1 qC
  15         115.1 CH     115.0 CH     115.8 CH     115.7 CH     122.3 CH     123.7 CH     123.8 CH     33.5 CH~2~
  16         163.8 qC     163.8 qC     165.4 qC     165.5 qC     163.9 qC     162.4 qC     205.1 qC     168.2 qC
  17         79.2 CH      79.1 CH      80.3 CH      80.3 CH      80.6 CH      78.2 qC      61.8 CH      81.2 CH
  18         19.6 CH~3~   19.6 CH~3~   15.8 CH~3~   15.8 CH~3~   19.6 CH~3~   13.2 CH~3~   24.2 CH~3~   14.1 CH~3~
  19         15.3 CH~3~   15.4 CH~3~   16.1 CH~3~   16.0 CH~3~   17.4 CH~3~   15.6 CH~3~   19.1 CH~3~   21.7 CH~3~
  20         119.6 qC     119.7 qC     119.9 qC     119.9 qC     119.6 qC     121.5 qC     36.8 CH      164.3 qC
  21         141.5 CH     141.5 CH     141.3 qC     141.3 CH     141.5 CH     142.3 CH     177.5 qC     72.4 CH~2~
  22         110.0 CH     110.1 CH     110.0 CH     110.0 CH     109.8 CH     109.7 CH     29.2 CH~2~   117.8 CH
  23         143.4 CH     143.4 CH     143.2 CH     143.2 CH     143.2 CH     144.9 CH     66.5 CH~2~   172.5 qC
  28         16.7 CH~3~   16.5 CH~3~   16.6 CH~3~   16.6 CH~3~   15.4 CH~3~   14.5 CH~3~   27.0 CH~3~   25.5 CH~3~
  29         49.7 CH~2~   49.6 CH~2~   43.1 CH~2~   43.1 CH~2~   40.5 CH~3~   39.0 CH~3~   21.3 CH~3~   21.4 CH~3~
  30         134.7 CH     134.8 CH     194.9 qC     195.0 qC     74.0 CH      78.2 CH      26.8 CH~3~   112.5 CH~2~
                                                                                           7-Acyl       
  31         53.2 CH~3~   53.2 CH~3~   53.3 CH~3~   53.3 CH~3~   53.2 CH~3~   52.3 CH~3~   169.8 qC     52.2 CH~3~
             3-Acyl       3-Acyl       3-Acyl       3-Acyl                                              
  32         170.4 qC     176.2 qC     174.3 qC     174.8 qC     119.5 qC     119.4 qC     21.0 CH~3~   
  33         20.6 CH~3~   40.7 CH      41.3 CH      34.2 CH      16.6 CH~3~   16.5 CH~3~                
                                                                 3-Acyl       3-Acyl                    
  34                      26.6 CH~2~   26.5 CH~2~   18.8 CH~3~   169.0 qC     167.8 qC                  
  35                      11.5 CH~3~   11.8 CH~3~   19.0 CH~3~   21.7 CH~3~   130.1 qC                  
                                                                 2-Acyl                                 
  36                      16.4 CH~3~   16.7 CH~3~                170.7 qC     139.7 CH                  
  37                                                             21.9 CH~3~   14.4 CH~3~                
  38                                                                          12.5 CH~3~                

[^1]: These authors contributed equally.
